A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus
Phase: PHASE3
Conditions: Type 2 Diabetes
Sponsor: Eli Lilly and Company

Protocol I4L-GH-ABET (a) 
 
 
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog 
LY2963016 to Lantus® in Adult Chinese Patients with Type 2 Diabetes Mellitus 
 
NCT03338010 
 
Approval Date: 2-Mar-2017 
 
 
 

I4L-GH-ABET(a) Clinical Protocol
Page 1
LY2963016
1.
Protocol I4L-GH-ABET(a)
A Prospective, Randomized, Open-Label Comparison of a 
Long-Acting Basal Insulin Analog LY2963016 to Lantus
®
in Adult Chinese Patients with Type 2 Diabetes Mellitus
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
LY2963016, unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries. This document and its associated attachments and 
appendices are subject to the United States Freedom of Information Act (FOIA), Exemption 
4.
LY2963016
Phase 3, randomized, multicenter, 2-arm, active-control, open-label, parallel, 24-week 
treatment study with a 4-week post-treatment follow-up to compare LY2963016 and 
Lantus
® in adult Chinese patients with type 2 diabetes mellitus.
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Electronically Signed and Approved by Lilly:  02 August 2016
Amendment (a) Electronically Signed and Approved by Lilly
on date provided below.
Approval Date: 02-Mar-2017 GMT

I4L-GH-ABET(a) Clinical Protocol
Page 2
LY2963016
2.
Synopsis
Study Rationale
LY2963016 is a highly similar version of Lantus
® (insulin glargine [recombinant 
deoxyribonucleic acid (rDNA) origin] injection), the reference medicinal product (also referred 
to as the innovator product) produced by Sanofi-Aventis (Lantus
® is a registered trademark of 
Sanofi-Aventis).  The primary amino acid sequence of LY2963016 is the same as that of the 
active ingredient in Lantus
®. Both LY2963016 and Lantus
® have similar formulations.  The 
present study is a randomized, open-label trial that will compare the efficacy and safety of 
LY2963016 to Lantus
® in adult Chinese patients with type 2 diabetes mellitus (T2DM).  The 
study patients will be insulin naïve and on 2 or more oral antihyperglycemic medications (OAMs)
with inadequate glycemic control.

I4L-GH-ABET(a) Clinical Protocol
Page 3
LY2963016
Clinical Protocol Synopsis:  Study I4L-GH-ABET
Name of Investigational Product:
LY2963016
Title of Study:  A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog 
LY2963016 to Lantus
® in Adult Chinese Patients with Type 2 Diabetes Mellitus
Number of Planned Patients/Subjects:
   Entered: 605
   Enrolled/Randomized:  530
   Completed:  450
Phase of Development:  Phase 3
Length of Study:
Estimated first patient visit:  Mar 2018               Estimated last patient visit:  Feb 2020
Objectives:  The primary objective of this study is to test the hypothesis that LY2963016 administered once daily 
(QD) is noninferior to Lantus
® (QD) by a 0.40% margin, as measured by change in hemoglobin A1c (HbA1c) from 
baseline to 24 weeks, when used in combination with OAMs.
The secondary objectives of the study are:

To test the hypothesis that Lantus
® is noninferior to LY2963016 (QD), as measured by change in HbA1c
from baseline to 24 weeks, when used in combination with OAMs. (this secondary objective is tested with 
a gated approach).

To compare safety of LY2963016 relative to Lantus
® (proportion of patients with detectable anti-glargine
antibodies, hypoglycemia, and injection site reaction) when used in combination with OAMs.

To compare change in HbA1c at 4, 8, 12, 16, and 20 weeks between LY2963016 and Lantus
® when used 
in combination with OAMs.

To compare 7-point self-monitored blood glucose (SMBG) profiles (as plasma equivalent values) at 0, 2, 
6, 12, and 24 weeks between LY2963016 and Lantus
® when used in combination with OAMs.

To compare percentage of patients with HbA1c <7% and percentage of patients with HbA1c ≤6.5% at 4, 
8, 12, 16, 20, and 24 weeks between LY2963016 and Lantus
® when used in combination with OAMs.

To compare LY2963016 to Lantus
® when used in combination with OAMs with regard to the following 
measures:
o
intrapatient blood glucose (BG) variability
o
basal insulin dose
o
Weight

To compare LY2963016 relative to Lantus
® for patient-reported outcomes (PRO) as measured by 
responses to the Insulin Treatment Satisfaction Questionnaire (ITSQ).
Study Design:  A Phase 3, prospective, randomized multicenter, 2-arm, active-control, open-label, parallel, 24-
week treatment and 4-week post-treatment follow-up study in adult Chinese patients with T2DM.  The study 
patients will be insulin naïve and on 2 or more OAMs with inadequate glycemic control.
Diagnosis and Main Criteria for Inclusion and Exclusions:
Patients with T2DM aged ≥18 with a body mass index (BMI) ≤35 kg/m
2, on 2 or more OAMs at stable doses for at 
least 12 weeks prior to Visit 1 and with HbA1c ≥7.0% and ≤11.0%, will be included in the study.
Patients with significant liver, cardiac, or gastrointestinal disease will be excluded. Patients with active cancer or 
cancer within the previous 5 years (with the exception of basal cell carcinoma or carcinoma in situ) will be 
excluded. Patients with hypersensitivity to Lantus
® or its excipients will be excluded.
Investigational Product, Dosage, and Mode of Administration or Intervention:
Patients will initiate treatment with a starting dose of 10 units (U) LY2963016 QD and will then be supervised by 
investigators through the course of the study to maintain the fasting blood glucose (FBG) ≤100 mg/dL 
(5.6 mmol/L) while avoiding hypoglycemia. The mode of administration will be subcutaneous.

I4L-GH-ABET(a) Clinical Protocol
Page 4
LY2963016
Planned Duration of Treatment:
Lead-in period:  None
Treatment period:  24 weeks
Washout period:  None
Observation period:  4 weeks
Reference Therapy, Dose, and Mode of Administration or Comparative Intervention:
Patients will initiate treatment with a starting dose of 10 U of Lantus
® QD and will then be supervised by 
investigators through the course of the study to maintain the FBG ≤100 mg/dL (5.6 mmol/L) while avoiding 
hypoglycemia. The mode of administration will be subcutaneous.
Criteria for Evaluation:
Efficacy
Primary Endpoint:
Change in HbA1c from baseline to 24 weeks.
Secondary Endpoints:

Change in HbA1c from baseline to 4, 8, 12, 16, and 20 weeks or last post-baseline observation carried 
forward (LOCF)

Percentage of patients with HbA1c <7%; percentage of patients with HbA1c ≤6.5%

7-point SMBG (expressed as plasma-equivalent glucose values obtained before each meal; after each 
meal; at bedtime)

Intrapatient variability as measured by the standard deviation (SD) of the 7-point SMBG

Basal insulin dose in total units per day and daily units per kilogram

Weight change

Patient-reported outcomes as reflected in responses to ITSQ
Safety:
Anti-glargine antibodies, laboratory measurements, adverse events (AEs), serious adverse events (SAEs), and 
hypoglycemia will be evaluated for safety. Episodes of severe hypoglycemia will be captured as SAEs. Certain 
outcomes, such as death, early discontinuation because of AE, and investigator decision to discontinue a subject 
will also be evaluated for safety. Patients will report hypoglycemia, which is defined as an event associated with 
signs or symptoms consistent with hypoglycemia or a blood level of ≤70 mg/dL (≤3.9 mmol/L), even if it is not 
associated with signs or symptoms.
Injection-site reactions and neoplasms will be captured as AEs.
Health Outcomes:
Patient-reported outcomes as reflected in responses to ITSQ. The ITSQ is a validated instrument containing 
22 items that assesses treatment satisfaction for persons with diabetes who are taking insulin.

I4L-GH-ABET(a) Clinical Protocol
Page 5
LY2963016
Statistical Methods:
Sample Size:
Based on the primary objective, to show noninferiority of LY2963016 to Lantus
® at the 0.40% noninferiority 
margin (NIM), 450 completers in total with a ratio 2:1 (LY2963016 versus Lantus
®) are needed at 24 weeks.  This 
calculation assumes no treatment difference in HbA1c between LY2963016 and Lantus
®, common SD of 1.3% for 
change from baseline in HbA1c, 0.05 two-sided significance level, and over 85% power.  Assuming a 15% dropout 
rate at 24 weeks, the required number of randomized patients is 530 in total (353 for LY2963016 and 177 for 
Lantus
®).  
Statistical:
The primary efficacy outcome will be the change in HbA1c level from baseline to 24 weeks.  The primary analysis 
will be a likelihood-based, mixed model repeated measure (MMRM) approach, treating the data as missing at 
random (MAR) for the full analysis set (FAS) population.  The MMRM model will evaluate the change from 
baseline in HbA1c level as the dependent variable with treatment (LY2963016, Lantus
®), entry use of insulin 
secretagogues (sulfonylurea [SU], meglitinide,  neither) , visit, and interaction between visit and treatment as fixed 
effects; the baseline value of HbA1c as a covariate; and a random effect for patient. Supportive analyses will be 
performed using the same MMRM model on per-protocol (PP) population and using an analysis of covariance 
(ANCOVA) model on FAS population. 
The analysis of the continuous secondary efficacy and safety measurements will use the same MMRM model for 
the primary efficacy analyses with the baseline value of the response as a covariate with the FAS patient 
population. Continuous laboratory measures will be analyzed using an ANCOVA model. For categorical 
measures, Fisher’s exact test or Pearson’s Chi-square test will be used.

I4L-GH-ABET(a) Clinical Protocol
Page 6
LY2963016
3.
Table of Contents
A Prospective, Randomized, Open-Label Comparison of a 
Long-Acting Basal Insulin Analog LY2963016 to Lantus
® in 
Adult Chinese Patients with Type 2 Diabetes Mellitus
Section
Page
1.
Protocol I4L-GH-ABET(a) A Prospective, Randomized, Open-Label 
Comparison of a Long-Acting Basal Insulin Analog LY2963016 to 
Lantus
® in Adult Chinese Patients with Type 2 Diabetes Mellitus.......................................1
2.
Synopsis .............................................................................................................................2
3.
Table of Contents................................................................................................................6
4.
Abbreviations and Definitions...........................................................................................12
5.
Introduction ......................................................................................................................16
6.
Objectives.........................................................................................................................18
6.1.
Primary Objective ........................................................................................................18
6.2.
Secondary Objectives...................................................................................................18
7.
Investigational Plan...........................................................................................................19
7.1.
Summary of Study Design............................................................................................19
7.2.
Discussion of Design and Control ................................................................................20
7.2.1.
Introduction .........................................................................................................20
7.2.2.
Study Visits..........................................................................................................21
7.2.2.1.
Screening (Visit 1)..........................................................................................21
7.2.2.2.
Randomization (Visit 2)..................................................................................21
7.2.2.2.1.
Patients Eligible for Randomization at Visit 2...........................................21
7.2.2.2.1.1.
Instructions for Insulin Self-Administration ........................................22
7.2.2.3.
Study Visits (Visit 3 to Visit 18).....................................................................22
7.2.2.3.1.
Telephone Visits (Visits 3, 5, 7, 9, 11, 13, 15, and 
Visit 17)....................................................................................................22
7.2.2.3.2.
Office Visits (Visits 4, 6, 8, 10, 12, 14, 16, and Visit 
18 or Early Discontinuation).....................................................................23
7.2.2.4.
Follow-up Visit (Visit 801).............................................................................24
7.2.3.
Blood Glucose Monitoring Plan ...........................................................................24
8.
Study Population...............................................................................................................26
8.1.
Inclusion Criteria..........................................................................................................26
8.2.
Exclusion Criteria ........................................................................................................27
8.2.1.
Rationale for Exclusion of Certain Study Candidates ...........................................28
8.3.
Discontinuations ..........................................................................................................29

I4L-GH-ABET(a) Clinical Protocol
Page 7
LY2963016
8.3.1.
Discontinuation of Inadvertently Enrolled Patients...............................................29
8.3.2.
Discontinuation of Investigational Product...........................................................29
8.3.3.
Patient Discontinuation from the Study ................................................................30
8.3.4.
Patients Lost to Follow-Up...................................................................................31
8.3.5.
Discontinuation of Study Sites .............................................................................31
8.3.6.
Discontinuation of the Study................................................................................31
9.
Treatment..........................................................................................................................32
9.1.
Treatments Administered .............................................................................................32
9.2.
Materials and Supplies .................................................................................................32
9.3.
Method of Assignment to Treatment ............................................................................33
9.4.
Rationale for Selection of Doses in the Study...............................................................33
9.5.
Selection and Timing of Doses.....................................................................................33
9.5.1.
Special Treatment Considerations ........................................................................34
9.6.
Continued Access to Investigational Product................................................................34
9.7.
Blinding .......................................................................................................................34
9.8.
Concomitant Therapy...................................................................................................35
9.8.1.
Antihyperglycemic Medications...........................................................................35
9.8.2.
Other Concomitant Therapy.................................................................................35
9.9.
Treatment Compliance .................................................................................................35
9.10. Hypoglycemic Episodes...............................................................................................36
10.
Efficacy, Health Outcome/Quality of Life Measures, Safety 
Evaluations, and Appropriateness of Measurements..........................................................38
10.1. Efficacy Measures........................................................................................................38
10.1.1.
Primary Measure..................................................................................................38
10.1.2.
Secondary Efficacy Measures...............................................................................38
10.2. Health Outcome/Quality of Life Measures ...................................................................38
10.3. Safety Evaluations........................................................................................................39
10.3.1.
Adverse Events ....................................................................................................39
10.3.1.1.
Serious Adverse Events ..................................................................................40
10.3.1.1.1.
Suspected Unexpected Serious Adverse Reactions....................................41
10.3.2.
Other Safety Measures .........................................................................................41
10.3.3.
Safety Monitoring ................................................................................................42
10.3.4.
Complaint Handling.............................................................................................42
10.4. Sample Collection and Testing.....................................................................................42
10.4.1.
Samples for Study Qualification and Health Monitoring.......................................43
10.4.2.
Samples for Biomarker Research..........................................................................43
10.4.2.1.
Nonpharmacogenetic Biomarker Evaluations..................................................43
10.4.3.
Samples for Immunogenicity Research.................................................................43

I4L-GH-ABET(a) Clinical Protocol
Page 8
LY2963016
10.5. Appropriateness of Measurements................................................................................44
11.
Data Quality Assurance.....................................................................................................45
11.1. Data Capture System....................................................................................................45
12.
Sample Size and Statistical Methods .................................................................................46
12.1. Determination of Sample Size ......................................................................................46
12.2. Statistical and Analytical Plans.....................................................................................46
12.2.1.
General Considerations ........................................................................................46
12.2.2.
Patient Disposition...............................................................................................47
12.2.3.
Patient Characteristics..........................................................................................47
12.2.4.
Concomitant Therapy...........................................................................................47
12.2.5.
Treatment Compliance .........................................................................................48
12.2.6.
Primary Efficacy Outcome and Methodology.......................................................48
12.2.7.
Secondary Efficacy Outcome and Methodology...................................................49
12.2.8.
Health Outcome/Quality of Life Analyses............................................................49
12.2.9.
Safety Analyses....................................................................................................49
12.2.9.1.
Immunogenicity Test Antibodies....................................................................49
12.2.9.2.
Exposure ........................................................................................................50
12.2.9.3.
Adverse Events...............................................................................................50
12.2.9.4.
Hypoglycemic Events.....................................................................................50
12.2.9.5.
Laboratory Measures ......................................................................................51
12.2.9.6.
Vital Signs......................................................................................................51
12.2.10. Subgroup Analyses ..............................................................................................51
12.2.11. Interim Analyses..................................................................................................52
13.
Informed Consent, Ethical Review, and Regulatory Considerations ..................................53
13.1. Informed Consent.........................................................................................................53
13.2. Ethical Review.............................................................................................................53
13.3. Regulatory Considerations ...........................................................................................54
13.3.1.
Investigator Information.......................................................................................54
13.3.2.
Protocol Signatures ..............................................................................................54
13.3.3.
Final Report Signature .........................................................................................55
14.
References ........................................................................................................................56

I4L-GH-ABET(a) Clinical Protocol
Page 9
LY2963016
List of Tables
Table
Page
Table ABET.9.1.
Algorithm for Titration of Basal Insulin Dose ...........................................34

I4L-GH-ABET(a) Clinical Protocol
Page 10
LY2963016
List of Figures
Figure
Page
Figure ABET.7.1.
Study design for Clinical Protocol I4L-GH-ABET....................................20

I4L-GH-ABET(a) Clinical Protocol
Page 11
LY2963016
List of Attachments
Attachment
Page
Attachment 1.
Protocol ABET Study Schedule......................................................................58
Attachment 2.
Protocol ABET Clinical Laboratory Tests.......................................................63
Attachment 3.
Protocol ABET Estimated Sampling Summary...............................................64
Attachment 4.
Protocol ABET Hepatic Monitoring Tests for Treatment 
Emergent Abnormality ......................................................................................................65
Attachment 5.
Protocol ABET World Health Organisation (WHO)
Classification of Diabetes..................................................................................................66
Attachment 6.
Protocol Amendment I4L-GH-ABET(a) Summary:  A Prospective, 
Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 
to Lantus® in Adult Chinese Patients with Type 2 Diabetes Mellitus.................................67

I4L-GH-ABET(a) Clinical Protocol
Page 12
LY2963016
4.
Abbreviations and Definitions
Term
Definition
ADA
American Diabetes Association
ACS
American Cancer Society
adverse event (AE)
Any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and that does not necessarily have a causal 
relationship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
ALT
alanine aminotransferase 
ANCOVA
analysis of covariance
AST
aspartate aminotransferase
audit
A systematic and independent examination of the trial-related activities and documents 
to determine whether the evaluated trial-related activities were conducted, and the data 
were recorded, analyzed, and accurately reported according to the protocol, applicable 
standard operating procedures (SOPs), good clinical practice (GCP), and the applicable 
regulatory requirement(s).
BG
blood glucose
blinding
A procedure in which one or more parties to the trial are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, blinding will remain in effect until final 
database lock.
BMI
body mass index
case report form (CRF) 
and electronic case 
report form (eCRF)
Sometimes referred to as clinical report form:  A printed or electronic form for 
recording study participants’ data during a clinical study, as required by the protocol.
CI
confidence interval
CIOMS
Council for International Organizations of Medical Sciences
complaint
A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance
Adherence to all the trial-related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory requirements.
consent
The act of obtaining informed consent for participation in a clinical trial from patients 
deemed eligible or potentially eligible to participate in the clinical trial.  Patients 
entered into a trial are those who sign the informed consent form directly or through 
their legally acceptable representatives.

I4L-GH-ABET(a) Clinical Protocol
Page 13
LY2963016
CRO
contract research organization
CRP (clinical research 
physician)
Individual responsible for the medical conduct of the study.  Responsibilities of the 
CRP may be performed by a physician, clinical research scientist, global safety 
physician or other medical officer.
CSR
clinical study report
ED
early discontinuation
ECG
electrocardiogram
efficacy
Efficacy is the ability of a treatment to achieve a beneficial intended result.
end of study (trial)
End of study (trial) is the date of the last visit or last scheduled procedure shown in the 
Study Schedule for the last active subject in the study.
enroll
The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
enter
Patients entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
FAS
full analysis set
FBG
fasting blood glucose
GCP
good clinical practice
GLP
glucagon-like peptide
HbA1c
hemoglobin A1c
HIV
human immunodeficiency virus
IB
investigator’s brochure
ICF
informed consent form
ICH
International Conference on Harmonisation
informed consent
A process by which a patient voluntarily confirms his or her willingness to participate 
in a particular trial, after having been informed of all aspects of the trial that are relevant 
to the patient’s decision to participate.  Informed consent is documented by means of a 
written, signed, and dated informed consent form.
institutional review 
board/ethical review 
board (IRB/ERB)
A board or committee (institutional, regional, or national) composed of medical and 
nonmedical members whose responsibility is to verify that the safety, welfare, and 
human rights of the patients participating in a clinical study are protected.
Intent(ion) to treat 
(ITT)
The principle that asserts that the effect of a treatment policy can be best assessed by 
evaluating on the basis of the intention to treat a patient (that is, the planned treatment 
regimen) rather than the actual treatment given.  It has the consequence that patients 
allocated to a treatment group should be followed up, assessed, and analyzed as 
members of that group irrespective of their compliance to the planned course of 

I4L-GH-ABET(a) Clinical Protocol
Page 14
LY2963016
treatment.
interim analysis
An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
product
A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
investigator
A person responsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible 
leader of the team and may be called the principal investigator.
ITSQ
Insulin Treatment Satisfaction Questionnaire
IWRS
interactive web-response system
legal representative
An individual, judicial, or other body authorized under applicable law to consent on 
behalf of a prospective patient to the patient’s participation in the clinical study.
LOCF
last-observation-carried-forward or last post-baseline observation carried forward
LSMean 
least-squares mean
MAR
missing at random
MedDRA
Medical Dictionary for Regulatory Activities
MMRM
Mixed Model Repeated Measure
NIM
noninferiority margin
NPH
neutral protamine hagedorn
OAM
oral antihyperglycemic medication
OM
observed margins
patient
A study participant who has the disease or condition for which the investigational 
product is targeted.
PG
plasma glucose
PP
per-protocol
PRO/ePRO
(electronic) patient-reported outcomes
QD
once daily
randomize
The act of assigning a patient to a treatment.  Patients who are enrolled/ randomized in 
the trial are those who have been assigned to a treatment.

I4L-GH-ABET(a) Clinical Protocol
Page 15
LY2963016
rDNA
recombinant deoxyribonucleic acid
SAE
serious adverse event
screen
The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.
SD
standard deviation
SMBG
self-monitored blood glucose or self-monitoring of blood glucose
Study entry
patients will be considered to have been entered into the study after they have signed 
the inform consent form
SU
sulfonylurea
subject
An individual who is or becomes a participant in clinical research, either as a recipient 
of the investigational product(s) or as a control.  A subject may be either a healthy 
human or a patient.
suspected unexpected 
serious adverse 
reactions (SUSARs)
Suspected unexpected serious adverse reactions are serious events that are not listed in 
the Investigator’s Brochure (IB) and that the investigator identifies as related to 
investigational product or procedure.
T2DM
type 2 diabetes mellitus
TEAR
treatment emergent antibody response
TEAE
Treatment-emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
U
unit(s)
ULN
upper limit of normal
WHO
World Health Organization

I4L-GH-ABET(a) Clinical Protocol
Page 16
LY2963016
A Prospective, Randomized, Open-Label Comparison of a 
Long-Acting Basal Insulin Analog LY2963016 to Lantus
® in 
Adult Chinese Patients with Type 2 Diabetes Mellitus
5.
Introduction
Medical therapy, in the majority of patients with type 2 diabetes mellitus (T2DM), must be 
advanced over the course of the disease in order to maintain optimal glycemic control.  As the 
disease progresses, beta-cell function deteriorates, often requiring individuals to add insulin to 
their medication regimen.  A consensus algorithm jointly written by the American Diabetes 
Association (ADA) and the European Association for the Study of Diabetes recommends insulin 
to be started with a single injection of intermediate or long-acting insulin at bedtime, or morning 
long-acting insulin (Nathan et al. 2009).  Several clinical trials have demonstrated similar overall 
glycemic control between Lantus
® (insulin glargine [recombinant deoxyribonucleic acid (rDNA)
origin]; [Sanofi - Aventis, Bridgewater, New Jersey, USA]) and human insulin isophane 
suspension (NPH), but with a lower risk of hypoglycemia with Lantus
® (Yki-Järvinen et al.
2000, 2006; Riddle et al. 2003; Rosenstock et al. 2005).  Available data demonstrating Lantus
®’s 
efficacy and enhanced safety profile, combined with its 24-hour duration of action, has made it 
the treatment of choice for health providers to enable patients with T2DM to achieve their 
clinical goals (Mathieu and Robbrecht 2008).
Lantus
® differs from human insulin in that the amino acid asparagine at position A21 is replaced 
by glycine and two arginines are added to the C-terminus of the B-chain.  These changes shift the 
isoelectric point, producing a solution that is completely soluble at pH 4.0.  When injected into 
the subcutaneous tissue, the acidic solution is neutralized (Pieber et al. 2000).  This leads to the 
formation of microprecipitates, from which small amounts of insulin glargine are released.  The 
slow dissolution of hexamers into dimers and, finally, monomers results in an extended duration 
of action without a pronounced peak (Lantus
® US package insert, 2010).  
LY2963016 is a highly similar version of Lantus® (insulin glargine [rDNA origin] injection), the 
reference medicinal product (also referred to as the innovator product) produced by Sanofi-
Aventis (Lantus® is a registered trademark of Sanofi-Aventis).  The primary amino acid 
sequence of LY2963016 is the same as that of the active ingredient in Lantus®.  Both 
LY2963016 and Lantus® have similar formulations. The clinical development program for 
LY2963016 has generated evidence substantiating the similar nature in terms of clinical 
pharmacokinetics and pharmacodynamics, safety, and efficacy of LY2963016 and Lantus®.  
Study I4L-MC-ABEC was a phase 3, double-blind, 24-week trial to compare the efficacy and 
safety of LY2963016 to Lantus® in patients with T2DM. The study demonstrated LY2963016 
was noninferior to Lantus®. Lantus® was also noninferior to LY2963016. Thus, LY2963016 
and Lantus® were considered to have equivalent efficacy. Severe hypoglycemia was the most
frequently reported serious adverse event (SAE; LY2963016:  2 patients [0.5%]; Lantus®:  3 
patients [0.8%]). There were no statistically significant differences between treatment groups for 
the overall incidence and overall rate of each category/subcategory of hypoglycemia. There 

I4L-GH-ABET(a) Clinical Protocol
Page 17
LY2963016
were no statistically significant differences between treatment groups for the incidence of 
treatment-emergent adverse events (TEAEs) at the preferred term level. There were no 
statistically significant treatment differences for the proportion of patients with detectable insulin 
antibodies (post-hoc analysis) at endpoint (last-observation-carried-forward or last post-baseline 
observation carried forward [LOCF]) or overall, or for the proportion of patients that developed a 
treatment emergent antibody response (TEAR) at endpoint (LOCF) or overall. The safety 
profiles for LY2963016 and Lantus® were similar; there were no new safety findings in either 
treatment group. The data from this trial demonstrate that LY2963016 provides a well- tolerated 
and effective once daily (QD) basal insulin option for treatment of patients with T2DM in 
combination with oral antihyperglycemic medications (OAMs), with an efficacy and safety 
profile similar to that of Lantus® (insulin glargine).
The present study is a randomized, open-label trial that will compare the efficacy and safety of 
LY2963016 to Lantus
® in Chinese patients with T2DM on 2 or more OAMs and with inadequate 
glycemic control (without insulin) at study entry. This study will expand the evaluation of the 
efficacy and safety of LY2963016 to a broader race/ethnic spectrum of patients with T2DM 
considering that the study population in Study ABEC was white (78.4%) and Asian (8.5%). 
The sponsor, monitor, and investigators will perform this study in compliance with the protocol, 
good clinical practice (GCP), International Conference on Harmonisation (ICH) guidelines, and 
applicable regulatory requirements.
More information about the known and expected benefits, risks and reasonably anticipated 
adverse events (AEs) of LY2963016 may be found in the Investigator’s Brochure (IB).
Information on AEs expected to be related to the investigational product may be found in Section 
7 (Development Core Safety Information) of the IB. Information on SAEs expected in the study 
population independent of drug exposure and that will be assessed by the sponsor in aggregate 
periodically during the course of the study, may be found in Section 6 (Effects in Humans) of the 
IB.

I4L-GH-ABET(a) Clinical Protocol
Page 18
LY2963016
6.
Objectives
6.1.
Primary Objective
The primary objective of this study is to test the hypothesis that LY2963016 administered QD is 
noninferior to Lantus
® administered QD by a margin of 0.40%, as measured by change in 
hemoglobin A1c (HbA1c) from baseline to 24 weeks, when used in combination with OAMs.
6.2.
Secondary Objectives
The secondary objectives of the study are as follows:

To test the hypothesis that Lantus
® is noninferior to LY2963016 (QD), as measured by 
change in HbA1c from baseline to 24 weeks, when used in combination with OAMs.
(this secondary objective is tested with a gated approach).

To compare safety of LY2963016 relative to Lantus
® (proportion of patients with 
detectable anti-glargine antibodies, hypoglycemia, and injection site reaction) when used 
in combination with OAMs. 

To compare change in HbA1c at 4, 8, 12, 16, and 20 weeks between LY2963016 and 
Lantus® when used in combination with OAMs.

To compare 7-point self-monitored blood glucose (SMBG) profiles (as plasma 
equivalent values) at 0, 2, 6, 12, and 24 weeks between LY2963016 and Lantus® 
when used in combination with OAMs.

To compare percentage of patients with HbA1c <7% and percentage of patients 
with HbA1c ≤6.5% at 4, 8, 12, 16, 20, and 24 weeks between LY2963016 and 
Lantus® when used in combination with OAMs.

To compare LY2963016 to Lantus® when used in combination with OAMs with 
regard to the following measures:
o
intrapatient blood glucose (BG) variability
o
basal insulin dose
o
weight change

To compare LY2963016 relative to Lantus
® for patient-reported outcomes (PRO) as 
measured by responses to the Insulin Treatment Satisfaction Questionnaire (ITSQ).

I4L-GH-ABET(a) Clinical Protocol
Page 19
LY2963016
7.
Investigational Plan
7.1.
Summary of Study Design
Study I4L-GH-ABET (ABET) is a Phase 3, prospective, randomized, multicenter, 2-arm, active 
control, open-label, parallel-design, 24-week study with a 4-week post-treatment follow-up.  The 
study will compare 2 long-acting basal insulin analogs (LY2963016 and Lantus
®) in patients 
with T2DM who are insulin naïve and have failed to achieve adequate glycemic control on at 
least 2 OAMs.  This study is designed to determine noninferiority of LY2963016 to Lantus
® in 
change in HbA1c from baseline when used to initiate insulin therapy in this patient population. 
A total of 530 patients are planned to be enrolled in the study, with a target to complete 450
patients.  Patients will be screened at Visit 1, and eligible patients will be randomized at Visit 2
to receive LY2963016 or Lantus
® QD with at least 2 OAMs for a period of 24 weeks at which 
the efficacy endpoint of change in HbA1c levels from baseline will be assessed.  
Patients will be contacted over the telephone in-between office visits (described as “Telephone 
Visits” in Section 7.2.2.3.1) to be queried about the entry in their diaries regarding any AEs, 
hypoglycemia, insulin self-administration, etc.
At approximately 4-week post-treatment endpoint (Visit 801), patients will have a final clinic
visit at which information will be collected according to the Study Schedule (Attachment 1).  
The starting dose is 10 units (U), which will be titrated by the weekly dosing algorithm as 
described in Section 9.5 until fasting blood glucose (FBG) reaches ≤100 mg/dL (5.6 mmol/L)
(weekly-base titration till Visit 10 and titration as needed afterwards.  The insulin doses can be 
adjusted between intervals at discretion of the investigators.  The titration procedure during the 
study will occur as described in Section 9.5.
End of study (trial) is the date of the last visit or last scheduled procedure shown in the Study 
Schedule for the last active patient in the study.
Figure ABET.7.1 illustrates the study design.

I4L-GH-ABET(a) Clinical Protocol
Page 20
LY2963016
Abbreviations:  OAM = oral antihyperglycemic medication; QD = once daily; 
* = telephone visit.
Figure ABET.7.1.
Study design for Clinical Protocol I4L-GH-ABET.
7.2.
Discussion of Design and Control
7.2.1. Introduction
The present study is a randomized, open-label trial that will compare the efficacy and safety of 
LY2963016 to Lantus® in patients with T2DM.  The study patients will be insulin naïve and on 
2 or more OAMs with inadequate glycemic control.
This study is designed to allow comparison of the 2 insulin analogs, with regard to efficacy and 
safety, when used as a basal insulin therapy in these patient populations.  The study design 
includes the following periods:  Screening, Randomization, Treatment Period (composed of a 
Titration Period and a Maintenance Period), and a Follow-up Period.  It is expected that most of 
the titration will be completed during the Titration Period (Week 0 through Week 12) such that a 
patient is on a relatively stable basal insulin dose during the Maintenance Period (Weeks 13 
through Weeks 24) during which adjustments to insulin dose would be for safety such as 
hypoglycemia or unacceptable hyperglycemia.

I4L-GH-ABET(a) Clinical Protocol
Page 21
LY2963016
7.2.2. Study Visits
7.2.2.1.
Screening (Visit 1)
Approximately 2 weeks prior to the start of the study, all potential study patients eligible for 
randomization will be screened after signing the informed consent form (ICF) and assigned a
patient number.  Medical history (including history of previous insulin exposure) and preexisting 
conditions, physical examination, height, weight, vital signs, electrocardiogram (ECG) readings, 
concomitant medications, and AEs will be recorded during this visit.  Laboratory assessments 
performed to determine eligibility for the study include pregnancy tests for females of child 
bearing potential, HbA1c, serum chemistry and hematology assays to be performed at a central 
laboratory (Attachment 1 and Attachment 2).  Patients who do not meet all the inclusion criteria 
at Visit 1 will be considered screen failures and will not be randomized to participate in the 
study.  Serum pregnancy tests will be performed on all females of childbearing potential at Visit 
1 and when clinically indicated.  Urine pregnancy tests at other visits can be accepted per local 
regulations.  A urine pregnancy test may be repeated locally for any visits if considered 
necessary by the investigators and/or in compliance with local regulations.
Each patient will be given a glucometer (and associated supplies) and training on the use of the 
glucometer to monitor their BG levels (i.e., 4-point and 7-point SMBG) during the study
(Section 7.2.3). Qualified medical staff will instruct patients about signs and symptoms of 
hypoglycemia and hyperglycemia and how to treat them. Patients will be given study diaries and 
associated training to record all BG levels, insulin doses, episodes of hypoglycemia, AEs, and 
any medications taken that occur throughout the study (Attachment 1).  If allowed by local law, 
patients may keep the study-provided BG meter at the end of their study participation.
7.2.2.2.
Randomization (Visit 2)
7.2.2.2.1. Patients Eligible for Randomization at Visit 2
At Visit 2, additional clinical and laboratory assessments will occur, as outlined in the Study 
Schedule (Attachment 1).  The following activities will occur at this visit:

Eligible patients will be randomized to 1 of the 2 treatment groups in a ratio of 2:1
(LY2963016 versus Lantus
®) by a web directed random assignment that is stratified by 
HbA1c levels (<8.5% versus ≥8.5%), and entry use of insulin secretagogues
(sulfonylurea [SU], meglitinide,  neither) .

Study material (for example, prefilled pen injector) will be dispensed at Visit 2 and at 
subsequent visits as indicated in the Study Schedule (Attachment 1).

Patients also will be instructed about diet and exercise and encouraged to maintain their 
same levels of activity throughout the study.

Study personnel will train patients on the injection technique of insulin, how to monitor 
their own BG levels (Section 7.2.3), and proper use of the study diary for recording BG 
values and corresponding insulin doses, hypoglycemic episodes, and AEs.

I4L-GH-ABET(a) Clinical Protocol
Page 22
LY2963016

Study diaries from Visit 1 will be collected, and patients will be given a new study diary 
at Visit 2 and each subsequent investigator-site visit.  The diaries will be source 
documents for the site of the patients’ record of their BG levels, insulin doses, and 
episodes of hypoglycemia that occur throughout the study.  The diaries will be collected 
at each subsequent investigator-site visit to transfer data and used by the investigator to 
determine any dose adjustments needed for a patient.

Patient safety will be assessed, including body weight, vital signs, and any AEs or 
hypoglycemic episodes that occurred since Visit 1.  Use of concomitant medications will 
be noted.

A blood sample will be drawn to determine the baseline HbA1c level.

A blood sample will be drawn to determine level of anti-glargine antibodies.

Blood samples will be drawn and stored during Visit 2 for biomarker assessment as 
warranted.  The sole purpose of this sample storage is to characterize patients’ drug 
response to therapy, for efficacy, lack of efficacy or unforeseen safety signals.

7-point SMBG profiles on 2 separate days will be performed in the 2-week period prior to 
Visit 2 (preferably most recent readings).
7.2.2.2.1.1.
Instructions for Insulin Self-Administration
Patients will administer their insulin dose subcutaneously (in the abdomen, upper arm, buttock, 
or thigh).  Patients should be trained by the site personnel on how to inject study insulin and to 
rotate site injections, following good practices for insulin administration.  The initial dose 10 U
will be injected by patients under guidance by the investigators at study site (Visit 2).  
Thereafter, the patient will self-administer insulin dose at bedtime (approximately the same time)
starting the day after Visit 2.  Dose adjustments for basal insulins are referred to Section 9.5.
Patients will be instructed to monitor themselves for any signs and symptoms of immediate or 
delayed hypersensitivity or allergic reactions following their injections.  Patients will be 
instructed to contact emergency medical services in case of severe reactions.
7.2.2.3.
Study Visits (Visit 3 to Visit 18)
Patients’ office visits will occur every 2 weeks between Visit 2 and Visit 10 and every 4 weeks 
between Visit 10 and Visit 18 (Attachment 1).  Additional training may be provided as deemed 
necessary during Visit 3 to Visit 18 on diary use, insulin injection technique, diet and exercise, or 
glucometer use.
Between each office visit, there are telephone visits (Visits 3, 5, 7, 9, 11, 13, 15, and Visit 17),
which are described separately.
7.2.2.3.1. Telephone Visits (Visits 3, 5, 7, 9, 11, 13, 15, and Visit 17)
Between each office visit, patients will have a telephone visit with the investigator at 1-week 
intervals after Visits 2, 4, 6, and Visit 8 and at 2-week intervals after Visits 10, 12, 14, and 16.

I4L-GH-ABET(a) Clinical Protocol
Page 23
LY2963016
The main purpose of telephone visits is to check SMBG values.  Because the study diaries are 
considered to be source documents, applicable data from telephone visits will be included and 
entered in the electronic case report form (eCRF) from the patient diary as part of the next office 
visit.
During telephone visits, the investigator or designee will inquire, record, and/or perform the 
following:

Blood glucose readings from the 4-point SMBG (once before each meal and at bedtime)
from 3 separate days (preferably most recent readings) (Attachment 1) since the last 
office visit (see Section 7.2.3 for further explanation).  Note that these values will need to 
be entered into the eCRF at the next office visit, once the values have been correlated 
with the study diary values.

Hypoglycemic episodes since last visit.

Previous day’s insulin dose.

Adjustment of insulin dose, if applicable.

Any AEs experienced and any changes in medications since last visit.

Reeducation of the patient as needed.

Preparation for next office visit.
Patients will retrieve information about BG values, previous day’s insulin dose, and 
hypoglycemic episodes from entries in their study diaries.  Telephone visits can also be 
conducted as office visits at the study site, if more practical.  Although 8 official telephone visits 
have been planned for this study, investigators may contact patients as frequently as necessary to 
adjust the insulin dose to achieve BG targets.  Specified data from telephone visits (Attachment 
1) will be recorded in the eCRFs from the diaries once they are collected from the patient at the 
next office visit.  
7.2.2.3.2. Office Visits (Visits 4, 6, 8, 10, 12, 14, 16, and Visit 18 or Early 
Discontinuation)
The following activities occur during investigator site Visits 4, 6, 8, 10, 12, 14, 16, and Visit 18
or Early Discontinuation (ED):

study diaries collected and reviewed for BG levels, episodes of hypoglycemia, insulin 
self-administration (Section 7.2.2.2)

distribute study diaries (not completed at ED)

dispense study drug with prefilled pen injector (not completed at Visits 4, 8, 18, or ED)

collect study drug at Visits 6, 10, 12, 14, 16, 18, and ED

collection of blood sample for HbA1c assessment to determine efficacy of treatment 
values for each patient at Visits 6, 10, 12, 14, 16, 18 or ED

I4L-GH-ABET(a) Clinical Protocol
Page 24
LY2963016

blood sampling for chemistry and hematology at Visit 18 or ED

transfer data from study diaries into eCRF (including previous day’s insulin dose from 
last telephone visit)

adjustment of insulin doses as needed during Visits 4, 6, 8, 10, 12, 14, and Visit 16 (not 
completed at Visits 18 or ED)

previous day’s insulin dose

assessment of vital signs, body weight

inquiries of AEs

inquire about use of concomitant medications

collection of blood sample to determine generation of anti-glargine antibodies at Visits 4, 
6, 12, and Visit 18 (or ED)

collection of serum samples for biomarker analysis during Visit 10 and Visit 18

administer the ITSQ questionnaires during Visits 6, 12, and Visit 18 (or ED)

dispense BG monitoring supplies as required
In addition to the daily BG monitoring, patients will be instructed to complete:

7-point SMBG profiles (described in Section 7.2.3) on 2 separate days in the 2-week 
period prior to Visits 4, 8, 12, and 18 (or at ED) (preferably most recent readings).

4-point SMBG values recorded (once before each meal and at bedtime) on 3 separate 
days before phone visits then transferred to the eCRF in succeeding office visit
(preferably most recent readings).
Patients are instructed on a post-treatment insulin regimen which is at discretion of the 
investigator (at Visit 18 or ED).
7.2.2.4.
Follow-up Visit (Visit 801)
Patients will come to the investigator site approximately 4 weeks after the last treatment visit, at
which time information will be discussed and recorded according to the Study Schedule
(Attachment 1). Note:  The previous day’s insulin dose will be recorded if the patient has
continued to take insulin.
Patients who discontinue early from the study will undergo all the end of study procedures and 
complete Visit 801 as outlined in Attachment 1.
7.2.3. Blood Glucose Monitoring Plan
Patients will be provided with glucometers and corresponding glucose test strips so they can 
obtain SMBG values.  Blood glucose values will be utilized to guide insulin titration dosing; to 
determine hypoglycemia, as specified in the protocol; and to ensure that uniform data are 
collected.  Glucose test strips will be distributed according to national regulations. 

I4L-GH-ABET(a) Clinical Protocol
Page 25
LY2963016
Throughout the study, patients will be instructed to check their FBG values daily to assess the 
need for dose adjustments.  The first recorded BG value for each profile should be a premorning 
meal BG value followed by the other specified BG values through the day for consistency.

In the week prior to telephone visits, patients will be instructed to complete 4-point 
SMBG values (once before each meal and at bedtime) recorded on 3 separate days
(preferably most recent readings).  Four-point SMBG values reported during telephone 
visits will be recorded at the subsequent office visit and Visit 801.

Patients will be instructed to complete 7-point SMBG profiles on 2 separate days in the 2-
week period prior to Visits 2, 4, 8, 12, and 18 (preferably most recent readings).  The 
SMBG profiles will consist of:
o
before the morning meal, midday meal, and evening meal; 2-hour postprandial 
measurements for the morning, midday meal, and evening meal; at bedtime.
o
In case of unexplained morning hyperglycemia, investigators shall instruct 
patients to conduct additional 3am and prebreakfast BG to identify the cause.
Missing values in SMBG profiles that do not reflect noncompliance with the protocol, in the 
opinion of the investigator, will not be considered a protocol deviation.
Patients may be requested by investigators to perform more intensive self-monitoring, if 
clinically indicated.  Patients should record all BG values in their study diaries.
The morning premeal measurement should be done fasting before breakfast.  Data from the 
7-point SMBG profiles measured prior to Visits 2, 4, 8, 12, and 18 will be used to assess the 
effect of the treatments on daily BG values and should, therefore, be transferred to the eCRF at 
those visits.  In the case of ED, 7-point SMBG values from the patient’s study diary after the 
previous office visit should be entered into the eCRF, as are available.  Patients should record all 
BG values (and insulin doses after Visit 2) in their study diaries.

I4L-GH-ABET(a) Clinical Protocol
Page 26
LY2963016
8.
Study Population
Patients who give written informed consent will be entered at Visit 1.  Patients who meet all of 
the inclusion/exclusion criteria will be randomized at Visit 2 and will receive study drug.  
Individuals who do not meet the criteria for participation in this study (screen failure) may not be 
rescreened.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, are not permitted.
8.1.
Inclusion Criteria
Patients are eligible to be included in the study only if they meet all of the following criteria:
[1]
Have T2DM based on the disease diagnostic criteria World Health 
Organization (WHO) classification (see Attachment 5).
[2]
If female patients, are women of child-bearing potential who test negative for 
pregnancy at the time of enrollment based on a serum pregnancy test and 
agree to use a reliable method of birth control during the study.
[3]
Are ≥18 years of age.
[4]
Have been receiving 2 or more OAMs at stable doses for the 12 weeks prior to 
Visit 1.  Note: use and dose of oral agents in combination with insulin must 
be in accordance with the local product label.  Doses of any OAMs are 
required to have been stable for the 12 weeks prior to Visit 1 and at least 2 of 
the OAMs must be dosed at or above half the maximum daily dose allowed by 
local regulations.
Patients taking metformin and who are found to have a contraindicated serum 
creatinine level (≥1.4 mg/dL [124 µmol/L] for females, ≥1.5 mg/dL
[133 µmol/L] for males) must be willing to discontinue use of metformin at 
randomization.
Note:  If on 2 OAMs at study entry and there is a need to discontinue one of 
those agents due to country labeling requirements or clinical parameters, that 
patient would not meet entry criteria.
[5]
Have an HbA1c ≥7.0% and ≤11.0%.
[6]
Body mass index (BMI) ≤35 kg/m2.
[7]
As determined by the investigator, are capable and willing to do the 
following:

perform SMBG

complete patient diaries as required

use prefilled pen injector according to study instructions

I4L-GH-ABET(a) Clinical Protocol
Page 27
LY2963016

are receptive to diabetes education

comply with required study treatment and study visits
[8]
Have given written informed consent to participate in this study in accordance 
with local regulations.
8.2.
Exclusion Criteria
Patients will be excluded from the study if they meet any of the following criteria:
[9]
Have used insulin therapy (outside of pregnancy) anytime in the past 1years, 
except for short-term treatment of acute conditions, and up to a maximum of 4 
continuous weeks.  Insulin use of any duration during pregnancy is not 
considered an exclusion criterion.
[10] Have used any glucagon like peptide (GLP-1) receptor agonists within the 
previous 90 days.
[11] Are currently taking traditional medicine (herbal medicine or patent medicine) 
with known/specified content of anti-hyperglycemic effects within 3 months 
before Visit 1.
[12] Have had more than one episode of severe hypoglycemia within 6 months 
prior to entry into the study.
[13] Have had ≥2 emergency room visits or hospitalizations due to poor glucose
control (e.g., ketoacidosis or hyperosmolar coma) in the 6 months prior to 
Visit 1.
[14] Have known hypersensitivity or allergy to Lantus
® or its excipients.
[15] Are receiving chronic (lasting longer than 14 consecutive days) systemic 
glucocorticoid therapy at pharmacological doses (excluding topical, intra-
articular, intraocular, or inhaled preparations and physiologic replacement 
doses for adrenal deficiency) or have received such therapy within 4 weeks 
immediately preceding Visit 1.
[16] Have obvious signs or symptoms, or laboratory evidence, of liver disease 
(alanine aminotransferase [ALT]; or aspartate aminotransferase [AST] greater 
than 2.5 times the upper limit of the reference range, as defined by the central
laboratory; or albumin value remarkably above or below the normal reference 
range, as defined by the central laboratory).
[17] Have one of the following concomitant diseases:  significant cardiac (for 
example, congestive heart failure Class III or IV) or gastrointestinal disease 
(for example, significant gastroparesis).
[18] Have a history of renal transplantation, are currently receiving renal dialysis 
or have a serum creatinine greater than 2.0 mg/dL (177 mol/L).

I4L-GH-ABET(a) Clinical Protocol
Page 28
LY2963016
[19] Have had a blood transfusion or severe blood loss within 3 months prior to 
Visit 1 or have known hemoglobinopathy, hemolytic anemia, or sickle cell 
anemia.
[20] Patients with active cancer or personal history of cancer within the previous 5 
years (with the exception of basal cell carcinoma or carcinoma in situ).
[21] Have a history or diagnosis of human immunodeficiency virus (HIV) infection.
[22] Are investigator site personnel directly affiliated with this study and/or their 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether biological or legally adopted.
[23] Have any other condition (including known drug or alcohol abuse or 
psychiatric disorder) that precludes the patient from following and completing 
the protocol.
[24] Are Lilly or Boehringer Ingelheim employees.
[25] Are currently enrolled in a clinical trial involving an investigational product or 
nonapproved use of a drug or device (other than the investigational product 
used in this study), or concurrently enrolled in any other type of medical 
research judged not to be scientifically or medically compatible with this 
study.
[26] Have previously completed or withdrawn from this study.
[27] Are pregnant or intend to become pregnant during the course of the study, or 
are sexually active women of childbearing potential not actively practicing 
birth control by a method determined by the investigator to be medically 
acceptable.
[28] Are women who are breastfeeding.
8.2.1. Rationale for Exclusion of Certain Study Candidates
Exclusion criterion [9] excludes patients who have received chronic insulin therapy except short-
term treatment.
Exclusion criteria [10 and 19] exclude medications or conditions that may cause HbA1c
lowering not attributable to the regimens being studied, or which could lead to misinterpretation 
of the results.
Exclusion criterion [11] excludes traditional medicine with anti-hyperglycemic effects due to 
safety concerns and leading to misinterpretation of the results.
Exclusion criterion [12] and [13] addresses the potential difficulty of distinguishing if severe 
hypoglycemia is related to study drugs or to poor glycemic control in patients with recurring 
episodes.
Exclusion criteria [14 to 21] represent clinical situations that may prevent patients from 
completing the protocol, or may influence the effect or safety of study regimens, or are serious 

I4L-GH-ABET(a) Clinical Protocol
Page 29
LY2963016
conditions that pose a risk for morbidity and mortality.  Exclusion criterion [20] allows 
investigators to exclude patients in whom there may be a concern for cancer occurrence or 
recurrence consistent with the ADA-American Cancer Society (ACS) consensus report’s 
recommendation.  According to this recommendation, patients with a very high risk of cancer 
occurrence (or for recurrence of specific cancer types) may require more careful consideration in 
choosing between available diabetes therapies (Giovannucci et al. 2010).
Exclusion criterion [15] relates to the negative effect of steroid therapy on the management of 
diabetes.
Exclusion criterion [23] permits investigators to exclude patients who meet all other inclusion 
and exclusion criteria but may not be appropriate study candidates.
Exclusion criteria [22] and [24] reduce potential bias due to conflict of interest.
Exclusion criterion [25] prevents a situation in which potential positive or negative outcomes 
may not be clearly attributable to the regimens in the study.
Exclusion criterion [26] eliminates the possibility of duplicate participation by a patient.
Exclusion Criteria [27] and [28] assure the safety of unborn or newborn children.
8.3.
Discontinuations
8.3.1. Discontinuation of Inadvertently Enrolled Patients
The criteria for enrollment must be followed explicitly.
If the investigator site identifies a patient who did not meet enrollment criteria and who was 
inadvertently enrolled, the sponsor must be notified.  If the sponsor identifies a patient who did 
not meet enrollment criteria and who was inadvertently enrolled, the investigator site will be 
notified.  A discussion must occur between the sponsor clinical research physician (CRP) and the 
investigator to determine whether the patient may continue in the study, with or without 
investigational product.  Inadvertently enrolled patients may be maintained in the study and on
investigational product when the Lilly CRP agrees with the investigator that it is medically
appropriate for that patient.  The patient may not continue in the study with or without 
investigational product if the Lilly CRP does not agree with the investigator’s determination it is
medically appropriate for the subject to continue.  The investigator must obtain documented 
approval from the Lilly CRP to allow the inadvertently enrolled patient to continue in the study 
with or without investigational product. 
8.3.2. Discontinuation of Investigational Product
Discontinuation of the investigational product for abnormal liver tests should be considered by 
the investigator when a study patient meets one of the following conditions after consultation 
with the Lilly designated medical monitor: 

ALT or AST >8X upper limit of normal (ULN)

ALT or AST >5X ULN for more than 2 weeks

I4L-GH-ABET(a) Clinical Protocol
Page 30
LY2963016

ALT or AST >3X ULN and total bilirubin level >2X ULN or prothrombin time >1.5X 
ULN

ALT or AST >3X ULN with the appearance of fatigue, nausea, vomiting, right upper-
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
Patients who discontinue the investigational product and/or study early will have ED procedures 
performed as shown in the Study Schedule (Attachment 1).
8.3.3. Patient Discontinuation from the Study
Patients will be discontinued from the study in the following circumstances:

If any of Exclusion criteria ([14 to 15], [17 to 20], [23], [25], and [27 to 28]) are observed 
or develop after entry.  In this case, the patient may be discontinued from the study at the 
next visit, or sooner, if patient safety is the rationale for the exclusion criterion

If there is a lack of efficacy or the need to intensify the patient’s treatment (Section 9.5.1) 
beyond basal insulin dosing, based on investigator discretion that the patient has not had 
adequate progress in the reduction of HbA1c levels in spite of adequate basal insulin 
titration and dosing.  For example:  Based on investigator clinical judgment, a patient 
may be deemed appropriate to discontinue from the study if he/she is consistently 
achieving target FBG levels ≤100 mg/dL (5.6 mmol/L), but HbA1c levels remain above 
8.0% on at least 2 consecutive occasions in the absence of any signs of continued
improvement.  Or, a patient may be deemed appropriate to discontinue from the study if 
he/she is not achieving target FBG levels ≤100 mg/dL (5.6 mmol/L) but is experiencing 
hypoglycemia that would preclude further basal insulin titration

If the patient is off study medication for more than 14 consecutive days

If the patient has used short/rapid-acting insulin for glucose control and management of 
diabetes during an acute illness/injury for more than 14 consecutive days

If the patient enrolls in any other clinical trial involving an investigational product or 
enrollment in any other type of medical research judged not to be scientifically or 
medically compatible with this study

Investigator Decision
o
if the investigator decides that the patient should be discontinued from the study
o
if the patient, for any reason, requires treatment with another therapeutic agent 
that has been demonstrated to be effective for treatment of the study indication, 
discontinuation from the study occurs prior to introduction of the new agent

Subject Decision 
o
if the patient or the patient’s designee, for example, parents or legal guardian 
requests to be withdrawn from the study

Sponsor Decision

I4L-GH-ABET(a) Clinical Protocol
Page 31
LY2963016
o
if Lilly or its designee stops the study or stops the patient’s participation in the 
study for medical, safety, regulatory, or other reasons consistent with applicable 
laws, regulations, and GCP

Adverse Event 
o
if the investigator decides that the patient should be withdrawn because of an SAE 
or a clinically significant laboratory value, the investigational product is to be 
discontinued and appropriate measures are to be taken.  Lilly or its designee is to 
be alerted immediately.  Refer to Safety Evaluations Section 10.3.
Randomized patients who discontinue the study early will have early discontinuation procedures 
performed as shown in the Study Schedule (Attachment 1).
8.3.4. Patients Lost to Follow-Up
A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.  Site personnel are expected to make 
diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise 
unable to be followed up by the site.
8.3.5. Discontinuation of Study Sites
Study site participation may be discontinued if Lilly or its designee, the investigator, or the 
ethical review board (ERB) of the study site judges it necessary for medical, safety, regulatory, 
or other reasons consistent with applicable laws, regulations, and GCP.
8.3.6. Discontinuation of the Study
The study will be discontinued if Lilly or its designee judges it necessary for medical, safety, 
regulatory, or other reasons consistent with applicable laws, regulations, and GCP.

I4L-GH-ABET(a) Clinical Protocol
Page 32
LY2963016
9.
Treatment
9.1.
Treatments Administered
All treatments will be administered within the product labeling in China, when applicable.  For 
LY2963016, administration is described in the protocol.  This study involves a comparison of
LY2963016 to Lantus
® administered QD subcutaneously.  Patients will continue their prestudy 
OAMs throughout the study.
Lantus
® or LY2963016 will be started from 10 U based on randomization.  Investigators will 
titrate insulins until a FBG ≤100 mg/dL (5.6 mmol/L).  The dosing algorithm is referred to 
Section 9.5.  The investigators will be responsible for dose adjustment in telephone or office 
visits.  The insulin doses can be adjusted between the intervals of visits at discretion of the 
investigators.
The investigator or his/her designee is responsible for the following:

explaining the correct use of the investigational agent(s) to the patient, 

verifying that instructions are followed properly, 

maintaining accurate records of investigational product dispensing and collection, and 

returning all unused medication to Lilly or its designee at the end of the study.
Patients taking insulin secretagogues must continue taking their prescribed dose throughout the 
study.  If the patient experiences hypoglycemia, the investigator should assess whether it can be 
attributed to causes other than the insulin secretagogue, such as missed meals, other changes in 
diet or exercise, or incorrect dosing/administration of insulin.  The investigator may decrease the 
dose or discontinue the insulin secretagogue only after consultation and approval by the Lilly 
CRP or designee, and this must be documented appropriately.
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or problem with the investigational product so that the situation can be assessed.
9.2.
Materials and Supplies
Clinical trial materials will be labeled and should be handled and stored according to the
respective country’s regulatory requirements.
The reference therapy (Lantus®) used in this clinical trial is approved for use in each respective
country.
Patients must continue to use their prestudy OAMs throughout the study (Section 9.8.1).  
Patients on metformin must continue or discontinue the use of metformin based on Inclusion 
Criterion [4].
Patients randomized to LY2963016 will be provided with LY2963016 as a 100 U/mL solution 
for injection in a prefilled pen injector.  Patients randomized to Lantus
® will be provided with 
Lantus® as a 100 U/mL solution for injection in prefilled pen injector.  In addition, a
commercially available glucometer will be provided with the necessary supplies.

I4L-GH-ABET(a) Clinical Protocol
Page 33
LY2963016
9.3.
Method of Assignment to Treatment
At Visit 1, patients will be assigned a patient number, and at Visit 2, those who are eligible to 
participate in the study will be assigned to 1 of the 2 treatment arms in a ratio of 2:1 (LY2963016 
versus Lantus®) by stratified randomization via random assignment using the interactive web
response system (IWRS).  To achieve group comparability, patients will be stratified by HbA1c
stratum (<8.5%, ≥8.5%), and entry use of insulin secretagogues (SU, meglitinide, neither).
9.4.
Rationale for Selection of Doses in the Study
Patients in both treatment groups will start with a single injection of basal insulin analog (either 
Lantus® or LY2963016).  As supported by nonclinical data demonstrating similar 
glucodynamics between Lantus® and LY2963016 (data on file), and clinical data demonstrating 
similar efficacy and safety between Lantus® and LY2963016 (Blevins et al. 2015; Rosenstock et 
al. 2015), these insulins will be dosed in a similar fashion based on the dosing algorithm 
described in the protocol.
Patients will be started on 10 U of Lantus® or LY2963016, based on randomization.  
Investigators will titrate insulins until a FBG ≤100 mg/dL (5.6 mmol/L) is achieved as described 
in Section 9.5.  It is expected that most of the titration will be completed during the Titration 
Period (Weeks 0 through 12) such that a patient is on a relatively stable basal insulin dose during 
the Maintenance Period (Weeks 13 through 24) during which adjustments to insulin dose would 
be for safety such as hypoglycemia or unacceptable hyperglycemia.
Patients will continue to use their prestudy OAMs throughout the study.
9.5.
Selection and Timing of Doses
All treatments will be administered according to the country-specific product labeling where 
applicable.  The starting dose for patients is 10 U QD.  The study insulin will be self-
administered by the patient at bedtime (approximately the same time) from the following day
after Visit 2.  The dosing time is chosen based on the China guideline for type 2 diabetes on 
initiation of basal insulin (Chinese Diabetes Society 2014).
Dose titration is investigator-driven.  From the telephone visit (Visit 3), the investigator will 
assess the patient’s glycemic control for the previous week (weekly-base titration till Visit 10
and bi-weekly titration as needed afterwards) and, if necessary, inform the patient about any 
needed dose adjustment.  The dose will be adjusted using the following dosing algorithm based 
on the patient’s BG.
Following initiation of LY2963016 or insulin glargine, investigators may make alterations to 
increase the doses recommended by the dose adjustment algorithm in situations where 
adjustment have not had the desired therapeutic effect after consultation with Lilly.  Dose 
increases must be made at weekly intervals within 8 weeks from study initiation and as needed in 
the rest of treatment.  The insulin doses can be adjusted between the intervals at discretion of the 
investigators.

I4L-GH-ABET(a) Clinical Protocol
Page 34
LY2963016
The treat-to-target FBG is ≤100 mg/dL (5.6 mmol/L).  The insulin dose titration will be based on 
the glucose pattern from 3 separate BG readings before breakfast (preferably most recent 
readings) prior to each contact/visit from previous 1-2 weeks.  The dose algorithm for 
LY2963016 or insulin glargine will be referred to Table ABET.9.1 (Davies et al. 2005).
Table ABET.9.1.
Algorithm for Titration of Basal Insulin Dose
Average BG Before Breakfast (for Titration of Evening 
Dose)
Increase in Basal Dose 
(Units)
<70 mg/dL (<3.9 mmol/L)
Decrease to previous lower dose*
70-<100 mg/dL (3.9-5.6 mmol/L)
No adjustment
100-<120 mg/dL (5.6-6.7 mmol/L)
0-+2 U (at discretion of the investigator)
120-<140 mg/dL (6.7-7.8 mmol/L)
+ 2 U
140-<180 mg/dL (7.8-10.0 mmol/L)
+ 4 U
≥180 mg/dL (>10.0 mmol/L)
+6-8 U (at discretion of the investigator)
* The patient will be administered with the previous lower dose if he/she has documented hypoglycemia or probable 
symptomatic hypoglycemia.
Abbreviations:  BG = blood glucose; U = unit(s).
The investigators will also have the discretion to decrease the dose if it is noted that patients are 
experiencing hypoglycemia.  Patients will continue to take prestudy OAMs at the same dose 
during the study, unless described otherwise for certain conditions prespecified in the protocol 
(Section 9.8).  The investigator may decrease the dose or discontinue the insulin secretagogue
only after consultation and approval by the Lilly CRP or designee, and this must be documented 
on a note-to-file.
9.5.1. Special Treatment Considerations
There is no plan for rescue therapy in this study.  Patients who do not respond to basal insulin 
treatment for glycemic control will be discontinued from the study as described in Section 8.3.1.
9.6.
Continued Access to Investigational Product
The Sponsor will not provide patients with ongoing supplies of study medication after they have 
completed the study treatment period because LY2963016 is experimental.
9.7.
Blinding
This is an open-label study where investigators, patients, study-site personnel, and study 
monitors are aware of the treatment assignment.  To minimize bias, an integrated summary of 
data will not be provided by the actual treatment group to the study team prior to the final 
database lock.  Unblinding of the patient study drug treatment assignment to the study team may 
occur in cases when an individual patient’s treatment assignment may need to be revealed for 
evaluation of the safety information or during review of SAEs or individual patient data.

I4L-GH-ABET(a) Clinical Protocol
Page 35
LY2963016
9.8.
Concomitant Therapy
9.8.1. Antihyperglycemic Medications
Generally, patients should continue use of their OAM regimen at screening and as described in 
Inclusion Criterion [4] (Section 8.1).  The investigator will carefully consider the potential 
drug-drug interactions and contraindications of the OAMs with respect to the study insulins. 
Patients will not be allowed any other medications to reduce BG besides those outlined in 
Exclusion Criterion [11] (Section 8.2). 
Patients taking insulin scretagogues must continue taking their prescribed dose throughout the 
study.  If the patient experiences hypoglycemia, the investigator should assess whether it can be 
attributed to causes other than the insulin scretagogues, such as missed meals, other changes in 
diet or exercise, or incorrect dosing/administration of insulin.  The investigator may decrease the 
dose or discontinue the insulin scretagogues only after consultation and approval by the Lilly 
CRP or designee, and this must be documented appropriately.
The intent of this study is that patients not deviate from their OAM regimen and that they only 
use the study insulin(s) prescribed for them during the study.  However, in emergencies, it may 
be necessary for patients to change their dose of OAMs and/or be treated with a nonstudy insulin. 
This will be allowed for up to 14 consecutive days.  If such a situation occurs more than once 
during the study, or lasts longer than 14 consecutive days, a decision to keep the patient in the 
study should be made only after consultation between the investigator and the Lilly CRP or 
medical designee.  The decision should be documented by a note to the investigator’s file.
Please refer to Section 8.3.1 to review the criteria for discontinuation of patients.
9.8.2. Other Concomitant Therapy
All concomitant therapies that are part of routine care are allowed and can be used during the 
study.
As described in Exclusion Criteria [9 to 11] (Section 8.2), patients should not take any other 
BG-lowering medications of any kind that are not allowed in the study.  Patients will be allowed 
to use any other concomitant medications they require during the study except systemic 
glucocorticoid therapy longer than 14 consecutive days’ duration (with the exception of topical, 
intra-articular, intraocular, and inhaled preparations).  Patients who receive excluded 
concomitant therapy will be discontinued from the study (Section 8.3.1).
9.9.
Treatment Compliance
The investigator will assess patient compliance at each visit, based on a review of the patient’s 
glycemic control, adherence to the visit schedule, dosing-titration algorithm, administration of 
study drug (including dosing time), completion of study diaries, and any other parameters the 
investigator deems necessary.  
Patients who are deemed noncompliant will receive additional diabetes education and training, as 
required, and the importance of compliance with the protocol will be reinforced.  Patients who, 

I4L-GH-ABET(a) Clinical Protocol
Page 36
LY2963016
in the opinion of the investigator, are deemed consistently noncompliant may be discontinued 
from the study.  No specific study data will be collected for analysis of treatment compliance 
and, therefore, will not be assessed or reported.
9.10. Hypoglycemic Episodes
Patients should check their BG level, whenever possible, if they have symptoms suggestive of 
hypoglycemia.  For each hypoglycemic episode, patients should record their BG level, associated 
symptoms, treatment, and outcome in the study diaries provided by the Sponsor via the 
investigator. 
When instructing patients on recognition and management of hypoglycemic episodes, a
hypoglycemic episode is defined as any time a patient feels that he/she is experiencing a sign or 
symptom that is associated with hypoglycemia, or has a BG level of ≤70 mg/dL (≤3.9 mmol/L), 
even if it was not associated with signs, symptoms, or treatment consistent with current 
guidelines (ADA 2005).
Note:  Episodes of severe hypoglycemia reported during the study should also be recorded as 
SAEs (Section 10.3.1.1).
Severe hypoglycemia:  An event requiring assistance of another person to actively administer 
carbohydrate, glucagon, or other resuscitative actions. During these episodes, the subject has an 
altered mental status, and cannot assist in his/her care, are semiconscious or unconscious, or 
experience coma with or without seizures, and may require parenteral therapy. Blood glucose 
measurements may not be available during such an event, but neurological recovery attributable 
to the restoration of BG concentration to normal is considered sufficient evidence that the event 
was induced by a low BG concentration (BG ≤70 mg/dL [3.9 mmol/L]).
Nocturnal hypoglycemia:  Any hypoglycemic event that occurs between bedtime and waking. 
Documented Hypoglycemia:

Documented symptomatic hypoglycemia: An event during which typical
symptoms of hypoglycemia are accompanied by plasma glucose (PG) ≤70
mg/dL (≤3.9 mmol/L).

Documented asymptomatic hypoglycemia: An event not accompanied by 
typical symptoms of hypoglycemia but with PG ≤70 mg/dL (≤3.9 mmol/L).

Documented unspecified hypoglycemia: An event during which PG ≤70
mg/dL (≤3.9 mmol/L) but no information relative to symptoms of 
hypoglycemia was recorded.
Probable symptomatic hypoglycemia: An event during which symptoms typical of
hypoglycemia are not accompanied by a PG determination but that was presumably caused by a 
PG concentration ≤70 mg/dL (≤3.9 mmol/L).
Relative hypoglycemia (also referred to as Pseudohypoglycemia): An event during which the 
person with diabetes reports any of the typical symptoms of hypoglycemia with a measured PG
concentration >70 mg/dL (>3.9 mmol/L) but approaching that level.

I4L-GH-ABET(a) Clinical Protocol
Page 37
LY2963016
Overall hypoglycemia: This optional category combines all cases of hypoglycemia
(documented hypoglycemia and probable symptomatic hypoglycemia, including severe
hypoglycemia) excluding the events of relative hypoglycemia. Nocturnal and severe
hypoglycemia are special cases of documented or probable hypoglycemia. If an event of
hypoglycemia falls into multiple subcategories, that event should only be counted once in this
category.

I4L-GH-ABET(a) Clinical Protocol
Page 38
LY2963016
10. Efficacy, Health Outcome/Quality of Life Measures, Safety 
Evaluations, and Appropriateness of Measurements
Study procedures and their timing (including tolerance limits for timing) are summarized in the 
Study Schedule (Attachment 1).
10.1. Efficacy Measures
10.1.1. Primary Measure
The primary efficacy measure is the change in HbA1c from baseline to 24 weeks.
10.1.2. Secondary Efficacy Measures
The following measures will be considered for the comparison of other aspects of overall 
glycemic control:

change in HbA1c from baseline to 4, 8, 12, 16, and 20 weeks or LOCF

percentage of patients with HbA1c <7%; percentage of patients with HbA1c ≤6.5%

7-point SMBG measurements, as listed in the Study Schedule (Attachment 1)
o
premeal for each meal
o
postmeal for each meal
o
bedtime

intrapatient variability, as measured by the standard deviation of the 7-point SMBG.Basal 
insulin dose (including U/day and U/kg/d)

weight change

patient-reported outcomes as reflected in responses to ITSQ
10.2. Health Outcome/Quality of Life Measures
Self-reported patient questionnaires will be utilized to compare health outcomes for the 
2 insulins being studied. These health outcomes, specific to treatment satisfaction, will be 
reflected in responses to ITSQ administered at Visits 6, 12, Visit 18 and ED if a patient received 
at least one dose of study insulin.
The ITSQ is a validated instrument containing 22 items that assesses treatment satisfaction for 
persons with diabetes on insulin (Anderson et al. 2004).  Items are measured on a 7-point scale, 
where lower scores reflect better outcomes.  In addition to an overall score, the items that make 
up the 5 domains of satisfaction are categorized as:

Inconvenience of Regimen (IR - 5 items)

Lifestyle Flexibility (LF - 3 items)

I4L-GH-ABET(a) Clinical Protocol
Page 39
LY2963016

Glycemic Control (GC - 3 items)

Hypoglycemic Control (HC - 5 items)

Satisfaction with the Insulin Delivery Device (DD - 6 items)
All individual patient-domain scores will be calculated as the sum of the items in the domain.  If 
item score is missing and less than 20% of the items within the domain are missing for that 
patient, then the mean of all other patients’ scores for that item will be imputed for the item.  
Otherwise, the domain score will be missing for the patient.
10.3. Safety Evaluations
Investigators are responsible for monitoring the safety of patients who have entered this study 
and alerting Lilly or its designee to any event that seems unusual, even if this event may be 
considered an unanticipated benefit to the patient.
The investigator is responsible for the appropriate medical care of patients during the study.
The investigator remains responsible for following, through an appropriate health care option, 
AEs that are serious (SAEs), considered related to the study treatment or the study, or that caused 
the patient to discontinue before completing the study. The patient should be followed until the 
event is resolved or explained.  Frequency of follow-up evaluation is left to the discretion of the 
investigator.
10.3.1. Adverse Events
Lilly has standards for reporting AEs that are to be followed, regardless of applicable regulatory 
requirements that may be less stringent.
Lack of drug effect is not an AE in clinical studies because the purpose of the clinical study is to 
establish drug effect.
Study site personnel will record the occurrence and nature of each patient’s preexisting 
conditions, including clinically significant signs and symptoms of the disease while under 
treatment in the study.
After the ICF is signed, site personnel will record any change in the condition(s) and the 
occurrence and nature of any AEs.  All AEs related to protocol procedures are reported to Lilly 
or designee.
In addition, all AEs occurring after the patient receives the first dose of investigational product 
must be reported to Lilly or its designee via eCRF.
Any clinically significant findings from ECGs, labs, vital sign measurements, or other 
procedures that result in a diagnosis should be reported to Lilly or its designee.
Investigators will be instructed to report to Lilly or its designee their assessment of the potential 
relatedness of each AE to protocol procedure, studied disease state, investigational product, 
and/or drug delivery system via eCRF.

I4L-GH-ABET(a) Clinical Protocol
Page 40
LY2963016
The investigator decides whether he or she interprets the observed AEs as either related to 
disease, to the study medication, study procedure, or other concomitant treatment or pathologies.  
To assess the relationship of the AE to the investigational product, the following terminologies 
are defined:

Related:  a direct cause and effect relationship between the study treatment and 
the AE is likely

Unrelated:  without question, the AE is definitely not associated with the study 
treatment
If a patient’s dosage is reduced or treatment is discontinued as a result of an AE, study-site 
personnel must clearly report to Lilly or its designee via eCRF the circumstances and data 
leading to any such dosage reduction or discontinuation of treatment.
10.3.1.1. Serious Adverse Events
Serious adverse event collection begins after the patient has signed informed consent and has 
received investigational product.  If a patient experiences an SAE after signing informed consent, 
but prior to receiving investigational product, the event will NOT be reported as serious unless 
the investigator feels the event may have been caused by a protocol procedure.
Planned surgeries should not be reported as SAEs unless the underlying medical condition has 
worsened during the course of the study.
Study site personnel must alert Lilly or its designee via a sponsor-approved method of any SAE
within 24 hours of investigator awareness of the event via a sponsor-approved method.  If alerts 
issued via telephone, they are to be immediately followed with official notification on study-
specific SAE forms.  This 24-hour notification requirement refers to the initial SAE information 
and all follow-up SAE information.
An SAE is any AE from this study that results in one of the following outcomes:

death

initial or prolonged inpatient hospitalization

a life-threatening experience (that is, immediate risk of dying)

persistent or significant disability/incapacity

congenital anomaly/birth defect

that which is considered significant by the investigator for any other reason
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered an SAE when, based upon appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition.

I4L-GH-ABET(a) Clinical Protocol
Page 41
LY2963016
For the purposes of this protocol, all episodes of severe hypoglycemia will be considered an 
SAE.  If the investigator believes that a reported SAE of hypoglycemia does not meet any of the 
specific criteria outlined above (that is, death, initial or prolonged inpatient hospitalization, a life-
threatening experience, persistent or significant disability/ incapacity, or congenital 
anomaly/birth defect), the outcome of “considered significant by the investigator for any other 
reason” should be selected in the eCRF.
When a condition related to LY2963016 or Lantus
® necessitates medical or surgical intervention 
to preclude either permanent impairment of a body function or permanent damage to a body 
structure, the serious outcome of “required intervention” will be assigned.
Serious adverse events occurring up to and including the patient’s last visit will be collected, 
regardless of the investigator’s opinion of causation, in the clinical data collection database and
the pharmacovigilance system at the sponsor.
Pregnancy (during maternal or paternal exposure to investigational product) does not meet the 
definition of an AE.  However, to fulfill regulatory requirements any pregnancy should be 
reported following the SAE process to collect data on the outcome for both mother and fetus.
Investigators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study (the patient summary CRF has been completed).  
However, if the investigator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study, and he/she considers the event reasonably possibly related to the 
study treatment or study participation, the investigator must promptly notify Lilly.
Information on SAEs expected in the study population independent of drug exposure and that 
will be assessed by the sponsor in aggregate periodically during the course of the trial may be 
found in the IB.
10.3.1.1.1.Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (SUSARs) are SAEs that are not listed in the IB 
and that the investigator identifies as related to investigational product or procedure.  Lilly has 
procedures for the recording and expedited reporting of SUSARs that are consistent with global 
regulatory regulations and detailed guidances and will be followed.
10.3.2. Other Safety Measures
Hypoglycemic events, vital signs, and weight will be collected as indicated in the Study 
Schedule (Attachment 1). Twelve-lead ECGs will be collected locally according to the Study 
Schedule (Attachment 1).
The ECG will be interpreted by a qualified physician (the investigator or qualified designee) at 
the site as soon after the time of ECG collection as possible, and ideally while the patient is still 
present, for immediate patient management and to determine whether the patient meets entry 
criteria.

I4L-GH-ABET(a) Clinical Protocol
Page 42
LY2963016
10.3.3. Safety Monitoring
The Lilly CRP or medical designee will monitor safety data throughout the course of the study.
Lilly will review SAEs within time frames mandated by company procedures.  The Lilly CRP or 
medical designee will, as is appropriate, consult with the functionally independent GPS 
therapeutic area physician or clinical scientist, and periodically review:

trends in safety data

laboratory analytes

adverse events
If a study patient experiences elevated ALT or AST ≥3X ULN or elevated total bilirubin ≥2X 
ULN, clinical and laboratory monitoring should be initiated by the investigator. Details for 
hepatic monitoring depend upon the severity and persistence of observed laboratory test 
abnormalities.  To ensure patient safety and comply with regulatory guidance, the investigator is 
to consult with the Lilly designated medical monitor regarding collection of specific 
recommended clinical information and follow-up laboratory tests.  See Attachment 2 and 
Attachment 4.
10.3.4. Complaint Handling
Lilly collects product complaints of investigational products and drug delivery systems used in 
clinical studies in order to ensure the safety of study participants, monitor quality, and to 
facilitate process and product improvements.
The investigator or his/her designee is responsible for handling the following aspects of the 
product-complaint process in accordance with the instructions provided for this study:

recording a complete description of the product complaint and any associated AEs using 
study-specific product-complaint forms, which are provided for this purpose

faxing the completed study-specific product-complaint form within 24 hours to Lilly or 
its designee
If the investigator is asked to return the product for investigation, he/she will return a copy of the 
study-specific product-complaint form along with the product.
10.4. Sample Collection and Testing
Attachment 1 lists the schedule for sample collections in this study.
Attachment 2 lists the specific laboratory tests that will be performed for this study.
Attachment 3 provides a summary of the estimated maximum number and volume of samples, 
for all sampling, during the study.

I4L-GH-ABET(a) Clinical Protocol
Page 43
LY2963016
10.4.1. Samples for Study Qualification and Health Monitoring
Blood and urine samples will be collected at the times specified in the Study Schedule 
(Attachment 1). Standard laboratory tests, including chemistry and hematology will be 
performed. The clinical laboratory tests including a pregnancy test will be performed at a central
laboratory. A urine pregnancy test may be repeated locally for any visits if considered necessary 
by the investigators and/or in compliance with local regulations. Attachment 2 lists the specific 
tests that will be performed for this study.
Investigators must document their review of each laboratory safety report.
Samples collected for specified laboratory tests will be destroyed within 60 days of receipt of the 
confirmed test results.  Tests are run and confirmed promptly whenever scientifically 
appropriate.  When scientific circumstances warrant, however, it is acceptable to retain samples 
to batch the tests run, or to retain the samples until the end of the study to confirm that the results 
are valid.  Certain samples may be retained for a longer period, if necessary, to comply with 
applicable laws, regulations, or laboratory certification standards.
10.4.2. Samples for Biomarker Research
10.4.2.1. Nonpharmacogenetic Biomarker Evaluations
This study will employ sample collection.  Samples will be collected for nonpharmacogenetic 
biomarker investigation where local regulations allow.  Fasting serum samples will be collected 
at the times specified in the Study Schedule (Attachment 1).
Fasting samples being collected will be used to measure C-peptide to support trial interpretation.
Samples will be coded with the patient number and may be stored for a maximum of 1 year 
following last patient visit for the trial at a facility selected by the Sponsor to enable further 
analysis of responses to the investigational products.  The duration allows the Sponsor to respond 
to regulatory requests related to the investigational products.
10.4.3. Samples for Immunogenicity Research
Blood samples for immunogenicity testing will be collected to determine antibody production
against LY2963016 or Lantus®. Immunogenicity will be assessed by a validated assay designed 
to detect anti-glargine antibodies in the presence of the investigational product. Antibodies may 
be further characterized and/or evaluated for their ability to neutralize the activity of the 
LY2963016 or Lantus®.
Samples may be stored for a maximum of 1 year following last patient visit for the trial at a
facility selected by the sponsor to enable further analysis of immune responses to LY2963016 or
Lantus®. The duration allows the sponsor to respond to regulatory requests related to the
investigational product.

I4L-GH-ABET(a) Clinical Protocol
Page 44
LY2963016
10.5. Appropriateness of Measurements
All efficacy and safety assessments included in this study are generally regarded as reliable and 
accurate with respect to diabetes mellitus.

I4L-GH-ABET(a) Clinical Protocol
Page 45
LY2963016
11. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the following:

provide instructional material to the study sites, as appropriate

sponsor a start-up training session to instruct the investigators and study coordinators.  
This session will give instruction on the protocol, the completion of the CRFs, and study 
procedures

make periodic visits to the study site

be available for consultation and stay in contact with the study-site personnel by mail, 
telephone, and/or fax

review and evaluate CRF data and use standard computer edits to detect errors in data 
collection

conduct a quality review of the database
In addition, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study site.  The study may be audited by Lilly or its 
representatives and/or regulatory agencies at any time.  Investigators will be given notice before 
an audit occurs.
To ensure the safety of participants in the study, and to ensure accurate, complete, and reliable 
data, the investigator will keep records of laboratory tests, clinical notes, and patient medical 
records in the patient files as original source documents for the study.  If requested, the 
investigator will provide the Sponsor, applicable regulatory agencies, and applicable ERBs with 
direct access to original source documents.
11.1. Data Capture System
An electronic data capture system will be used in this study.  The site maintains a separate source 
for the data entered by the site into the Sponsor-provided electronic data capture system.
Case report form data will be encoded and stored in a clinical trial database.  Data managed by a 
central vendor, such as laboratory test data or will be stored electronically in the central vendor’s 
database system.  Data will subsequently be transferred from the central vendor to the Lilly 
generic labs system.
Any data for which the paper documentation provided by the patient will serve as the source 
document will be identified and documented by each site in that site’s study file.  Paper 
documentation provided by the patient may include, for example, a paper diary to collect PRO 
measures (for example, a rating scale), a daily dosing schedule, or an event diary.
Data from study-specific product-complaint forms submitted to Lilly will be encoded and stored 
in the global product-complaint management system.

I4L-GH-ABET(a) Clinical Protocol
Page 46
LY2963016
12. Sample Size and Statistical Methods
12.1. Determination of Sample Size
Based on the primary objective, to show noninferiority of LY2963016 to Lantus
® at the 0.40% 
noninferiority margin (NIM), 450 completers in total with a ratio 2:1 (LY2963016 versus 
Lantus®) are needed at 24 weeks.  This calculation assumes no treatment difference in HbA1c
between LY2963016 and Lantus®, common SD of 1.3% for change from baseline in HbA1c, 
0.05 two-sided significance level, and over 85% power.  Assuming a 15% dropout rate at 
24 weeks, the required number of randomized patients is 530 in total (353 for LY2963016 and 
177 for Lantus®).
12.2. Statistical and Analytical Plans
12.2.1. General Considerations
All data will be entered, verified, and archived by a contract research organization (CRO) 
external to Lilly and/or at Lilly.  Data listings, summaries, and analyses will be performed by a 
CRO and/or by Lilly under the guidance and approval of statisticians at Lilly.  Statistical analysis 
of this study will be the responsibility of Lilly.
Any change to the data-analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the justification for making the change, will be described 
in the statistical analysis plan and/or in the clinical study report (CSR).  Additional exploratory 
analyses will be conducted as deemed appropriate.
The patient populations used in the study are described below: 
1. All Patients Entered - all patients who entered this study and completed Visit 1
2. All Randomized - all patients who were randomized to a treatment arm
3. Full Analysis Set (FAS) - based on the intent to treat (ITT) principle, all patients
who were randomized and who have taken at least one dose of study medication
will be included in this analysis set.  Patients will be analyzed according to the 
treatments to which they were randomized.
4. Per-protocol (PP) - patients in the FAS/ITT population who also meet the 
following criteria:
a.
have no violations of Inclusion/Exclusion Criteria
b. have not discontinued from the study prior to 24 weeks
c.
have not been off study medication for more than 14 consecutive days
during the treatment period
d. have not received chronic (lasting longer than 14 consecutive days) 
systemic glucocorticoid therapy (excluding topical, intra-articular, 
intraocular, and inhaled preparations)

I4L-GH-ABET(a) Clinical Protocol
Page 47
LY2963016
Efficacy and safety analyses will be conducted using the FAS population. Selected analyses will 
be conducted using the All Randomized population and the PP population.  
Unless otherwise noted, all tests of treatment effects will be conducted at a 2-sided alpha level 
of 0.05, and confidence intervals (CIs) will be calculated as 2-sided 95% CIs. All tests of 
interactions between treatment groups and other factors will be conducted at a 2-sided alpha 
level of 0.05.  No adjustments for multiplicity will be performed.  
The baseline is Visit 2. If baseline data are missing, the last measurement taken prior to this visit 
will be used for the baseline measurement.
The analysis of the continuous secondary efficacy and safety measurements will use the same 
mixed model repeated measure (MMRM) model for the primary efficacy analyses with the 
baseline value of the response as a covariate with the FAS patient population. Continuous 
laboratory measures will be analyzed using an analysis of covariance (ANCOVA) model. For 
categorical measures, Fisher’s exact test or Pearson’s Chi-square test will be used.
All analyses will be implemented using SAS Version 8.2® or higher.
12.2.2. Patient Disposition
All patients who discontinue from the study will be identified, and the extent of their 
participation in the study will be reported.  If known, a reason for their discontinuation will be 
given.
A listing of the primary reason for patient discontinuation will be presented for all randomized 
patients.  Summary analyses will be conducted for the randomized and FAS populations.  
Frequency counts and percentages will be presented for each treatment group and compared 
across treatment groups using Fisher’s exact test or Pearson’s Chi-square test.
12.2.3. Patient Characteristics
The patient’s age, sex, weight, height, BMI, or other demographic characteristics will be 
recorded.
Demographic and baseline characteristics will be summarized by treatment group for the FAS 
and PP populations.  For continuous measures, summary statistics will include sample size, 
mean, median, maximum, minimum and SDs.  The treatment groups will be compared using a 
2-sample t test.  For categorical measures, summary statistics will include sample size, 
frequency, and percent.  Analysis will use Fisher’s exact test or Pearson’s Chi-square test.
12.2.4. Concomitant Therapy
Concomitant medications, including previous therapy for diabetes, will be summarized by 
different categories and treatment group using the FAS population.  All concomitant therapies 
that originally mapped using the WHODRUG dictionary in the Clintrial database will be further 
classified using anatomical therapeutic chemical codes for reporting purposes.  Analysis will use 
Fisher's exact test or Pearson’s Chi-square test.

I4L-GH-ABET(a) Clinical Protocol
Page 48
LY2963016
12.2.5. Treatment Compliance
No specific study data will be collected for analysis of treatment compliance.
12.2.6. Primary Efficacy Outcome and Methodology
The primary efficacy outcome will be the change in HbA1c level from baseline to 24 weeks.  
The primary analysis will be a likelihood-based, MMRM approach, treating the data as missing 
at random (MAR) for the FAS population.  The MMRM model will evaluate the change from 
baseline to each post-baseline visit in HbA1c level as the dependent variable with treatment 
(LY2963016, Lantus®), entry use of insulin scretagogue (SU, meglitinide, neither), visit, and 
interaction between visit and treatment as fixed effects; the baseline value of HbA1c as a 
covariate; and a random effect for patient.  The MMRM model will be carried out using the 
observed margins (OM) option in SAS.  Using this option weights the levels of the independent 
or stratification variables according to the observed marginal distribution.  This will provide 
least-squares means (LSMeans) for these outcomes that are more representative of the patient 
population recruited in this study.
The primary treatment comparison is to compare LY2963016 versus Lantus® at the NIM 
of +0.4%.  If the upper limit of the 95% CI on the change from baseline to 24-week endpoint 
HbA1c for LY2963016 versus Lantus® is below +0.4%, then LY2963016 will be declared 
noninferior to Lantus®. The LSMean and standard error derived from the MMRM model for 
each treatment will be used to test noninferiority. Type III sums of squares will be used to make 
the treatment comparisons.  

If the +0.4% NIM is met, a key secondary treatment comparison is to compare Lantus®
versus LY2963016 at the NIM of -0.4%. If the lower limit of the 95% CI on the change 
in HbA1c from baseline to the 24-week endpoint for LY2963016 versus Lantus® is 
above -0.4%, then Lantus® will be declared noninferior to LY2963016. The LSMean 
and standard error derived from the MMRM model for each treatment will be used to test 
noninferiority. This gate-keeping procedure controls the family-wise Type 1 error rate at 
a 1-sided 0.025 level.

If LY2963016 is declared noninferior to Lantus® in the primary treatment comparison,
and Lantus® is declared noninferior to LY2963016 in this secondary treatment 
comparison, then LY2963016 will be considered to have equivalent efficacy as Lantus®.
A first secondary analysis of the primary efficacy outcome will use the same MMRM model 
described above with the PP patient population. Significance tests will be based on LSMeans
using the Type III sum of squares, and testing for noninferiority will occur as described above.
A second secondary analysis of the primary efficacy outcome will use an ANCOVA model with 
FAS population. The ANCOVA model will include treatment and entry use of insulin 
screatagogue (SU, meglitinide, neither) as fixed effects and the baseline value of HbA1c as a 
covariate.  The ANCOVA model will be carried out using the OM option in SAS. If the 24-
week HbA1c value is missing, the last post-baseline value will be carried forward and used in the 
analysis.  This creates the 24-week endpoint value for HbA1c using the LOCF methodology.  If 

I4L-GH-ABET(a) Clinical Protocol
Page 49
LY2963016
there are no HbA1c data after the date of randomization, the endpoint will be considered missing 
and the patient will not be included in the analysis.
The analyses of the primary efficacy outcome will only be conducted for patients with both 
nonmissing baseline value and at least 1 nonmissing post-baseline value.
12.2.7. Secondary Efficacy Outcome and Methodology
The continuous secondary efficacy outcomes include:

change in HbA1c from baseline to 4, 8, 12, 16, and 20 weeks or LOCF

7-point SMBG measurements as listed in the Study Schedule (Attachment 1)
o
premeal for each meal
o
postmeal for each meal
o
bedtime

intrapatient variability, as measured by the SD of the 7-point SMBG

basal insulin dose (24-hour total measured in U/d and U/kg) at end of study

weight change
The analysis of the continuous secondary efficacy variables will be performed using the same 
MMRM model for the primary efficacy analysis with the baseline value of the response variable 
added as a covariate with the FAS population.  The proportion of patients achieving HbA1c
target values (HbA1c level <7.0% and ≤6.5%) at any point during the study (Weeks 4, 8, 12, 16, 
20, and 24 and 24-week endpoint [LOCF]) will be analyzed using Fisher’s exact test or 
Pearson’s chi-square test.
12.2.8. Health Outcome/Quality of Life Analyses
The ITSQ will be completed at Weeks 4 (Visit 6), 12 (Visit 12) and 24 (Visit 18) or ED.  
Responses at each of these weeks will be analyzed using the MMRM model for the FAS 
population as detailed above.
All individual patient-domain scores will be calculated using the nonmissing items and imputing 
the missing values as the mean of all other patients for the nonmissing items where at least 20%
of the items are nonmissing.  Otherwise, the domain scores will be missing for the patient.
12.2.9. Safety Analyses
12.2.9.1. Immunogenicity Test Antibodies
The proportion of patients with detected anti-glargine antibodies will be summarized as counts 
and percentages at baseline, at visit 6 and 12, at the 24-week endpoint (LOCF), and overall for 
the 24-week treatment period.  At each of these time points, the proportion of patients with 
detected antibodies will be compared between treatment groups using Fisher’s exact test.  The 
level of anti-glargine antibodies (percentage binding) will be summarized by descriptive 

I4L-GH-ABET(a) Clinical Protocol
Page 50
LY2963016
statistics (mean, median, SD, standard error, minimum, and maximum) at baseline, indicated
visits, and endpoint (LOCF).  At each of these time points, the level of percentage binding will 
be compared between treatment groups using the Wilcoxon rank sum test.  The relationship 
between the level of anti-glargine antibodies detected and clinical outcomes (HbA1c, total 
hypoglycemia, basal dose [U/day, U/kg/day]) will be investigated.
12.2.9.2. Exposure
Duration of exposure to each treatment will be calculated for each patient and summarized by 
descriptive statistics.
12.2.9.3. Adverse Events
Adverse events will be listed by patient, system organ class, Medical Dictionary for Regulatory 
Activities® (MedDRA) preferred term, severity, and relationship to the study disease, drug, 
device, or procedure for all patients.  Adverse events (including injection site reactions, allergic 
events, and neoplasms) will be summarized as TEAEs for the FAS.  Treatment-emergent adverse 
events are defined as events that are newly reported after first study treatment following 
randomization or reported to have worsened in severity from baseline.  The proportion of 
patients experiencing each TEAE will be presented by preferred term, system organ class, and 
treatment group.  The proportion of patients experiencing each TEAE that is assessed as possibly 
related to the study disease, drug, device, or procedures will also be summarized.  The number of 
patients and proportion will be presented and compared by treatment using Fisher’s exact test or 
Pearson’s chi-square test and will be utilized for the FAS. 
Injection site AEs will be evaluated for pain, pruritus, and rash associated with the injection, as 
well as the characteristics of the injection site (abscess, nodule, lipoatrophy, lipohypertrophy, or 
induration). The incidences of injection site AEs and allergic events by treatment group will be 
compared using Fisher’s exact test or Pearson’s chi-square test for the FAS population.
All SAEs will be listed by patient.  If a sufficient number of SAEs are reported, they will be 
summarized by treatment for all randomized patients.  Discontinuations due to TEAEs will be 
listed by patient.  If a sufficient number of discontinuations are reported, they will be 
summarized by treatment.
12.2.9.4. Hypoglycemic Events
The incidence, rate per 30 days and rate per year of hypoglycemic episodes (total, severe, and 
nocturnal as defined in Section 9.10) will be summarized by treatment at baseline, titration, 
maintenance, and overall study periods and at endpoint.  The rate per 30 days between two visits 
is defined as the total number of episodes between the visits divided by the actual number of 
days between the visits, and then multiplied by 30 days.
The proportion of patients (with at least 1 hypoglycemic event (total, severe, nocturnal, and 
others) or incidence during the study will be summarized (counts and percentages) and analyzed 
using Fisher’s exact test or the Pearson’s chi-square test for the FAS population.
The rate of hypoglycemic episodes per 30 days and per year (total, severe, nocturnal, and others) 
will be analyzed at baseline, titration, maintenance, and overall study periods and at endpoint

I4L-GH-ABET(a) Clinical Protocol
Page 51
LY2963016
using the Wilcoxon test. In addition, the hypoglycemia rates will also be analyzed using a 
negative binomial model for the FAS population with terms for treatment, baseline HbA1c, and
entry use of insulin secretagogues (SU, meglitinide, neither). The offset variables are log of 
patient’s treatment duration/30 and log of patient’s treatment duration/365.25 for the models 
analyzing hypoglycemia rate per 30 days and per year, respectively.
In addition, the total number of patients with at least 1 hypoglycemic episode divided by the total 
extent of exposure in patient-years will be calculated for the overall study period and 
summarized descriptively for each treatment group for total, severe, nocturnal, documented 
symptomatic, and asymptomatic hypoglycemia definitions only.  Listings of hypoglycemic 
episodes will be presented by visit for each subject.
12.2.9.5. Laboratory Measures
Continuous measures in the chemistry and hematology panels for the FAS population will be 
summarized at baseline.
Chemistry and hematology laboratory measures will be summarized as change from baseline to 
each postbaseline visit.  The continuous measures and change from baseline values to 24 weeks 
will be analyzed using the ANCOVA model with treatment, entry use of insulin secretagogues
(SU, meglitinide, neither) as fixed effects and the baseline value of HbA1c and the baseline of 
the response variable as covariates.  The ANCOVA model will be carried out using the OM 
option in SAS.
12.2.9.6. Vital Signs
Systolic blood pressure, diastolic blood pressure, and heart rate will be summarized by 
descriptive statistics (mean, median, SD, standard error, minimum, and maximum) by visit for 
the FAS population.  Additionally, change from baseline to each postbaseline visit will be 
summarized.  Change from baseline values to each postbaseline visit will be analyzed for the 
FAS population using the same MMRM model as in the primary efficacy analyses.
12.2.10. Subgroup Analyses
The consistency of the treatment effect will be assessed in the following subgroups in the FAS, if 
there are a sufficient number of patients in each treatment by subgroup:

entry HbA1c levels (<7%, ≥7%) 

entry HbA1c levels (<8.5%, ≥8.5%)

entry BMI (<30, ≥30) 

entry age (<65, ≥65)

entry use of insulin secretagogues (SU, meglitinide, neither)
The change in HbA1c from baseline to 24-week endpoint will be analyzed using MMRM with 
treatment, visit, entry use of insulin secretagogues (SU, meglitinide, neither), subgroup, 
subgroup-by-treatment interaction, subgroup-by-visit interaction, treatment-by-visit interaction, 

I4L-GH-ABET(a) Clinical Protocol
Page 52
LY2963016
and treatment-by-visit-by-subgroup interaction as fixed-effects, the baseline value of HbA1c as a 
covariate, and a random effect for patient for the FAS. If the subgroup is one of the stratification 
variables, then the subgroup will only be included once in the model. A significant treatment-
by-subgroup interaction (p<.05) may be indicative of a differential treatment effect across levels 
of the subgroup, necessitating further exploration of the nature of the interaction. 
Other subgroup analyses may be performed if deemed appropriate as exploratory analyses.
12.2.11.
Interim Analyses
No interim analyses are planned for this study.  If an unplanned interim analysis is deemed 
necessary, the appropriate Lilly medical director, or designee, will be consulted to determine 
whether it is necessary to amend the protocol.

I4L-GH-ABET(a) Clinical Protocol
Page 53
LY2963016
13. Informed Consent, Ethical Review, and Regulatory 
Considerations
13.1. Informed Consent
The investigator is responsible for ensuring:

that the patient understands the potential risks and benefits of participating in 
the study

that informed consent is given by each patient or legal representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
performance of any protocol procedures and prior to the administration of 
investigational product

answering any questions the patient may have throughout the study and 
sharing in a timely manner any new information that may be relevant to the 
patient’s willingness to continue his or her participation in the trial
A legal representative must give informed consent for a child to participate in this study.  In 
addition to informed consent given by the legal representative, the child may be required to give 
documented assent, if capable.
The investigator is responsible for ensuring that the patient understands the potential risks and 
benefits of participating in the study, including answering any questions the patient may have 
throughout the study and sharing in a timely manner any new information that may be relevant to 
the patient’s willingness to continue his or her participation in the trial.
The ICF will be used to explain the potential risks and benefits of study participation to the 
patient in simple terms before the patient is entered into the study and to document that the 
patient is satisfied with his or her understanding of the risks and benefits of participating in the 
study and desires to participate in the study.
The investigator is responsible for ensuring that informed consent is given by each patient or 
legal representative.  This includes obtaining the appropriate signatures and dates on the ICF 
prior to the performance of any protocol procedures and prior to the administration of 
investigational product.
As used in this protocol, the term “informed consent” includes all consent and assent given by 
patients or their legal representatives.
13.2. Ethical Review
Lilly or its representatives must approve all ICFs before they are used at investigative sites(s).  
All ICFs must be compliant with the ICH guideline on GCP.
The investigator must give assurance that the ERB was properly constituted and convened as 
required by ICH guidelines and other applicable laws and regulations.

I4L-GH-ABET(a) Clinical Protocol
Page 54
LY2963016
Documentation of ERB approval of the protocol and the ICF must be provided to Lilly before the 
study may begin at the investigative site(s).  Lilly or its representatives must approve the ICF, 
including any changes made by the ERBs, before it is used at the investigative site(s).
The study site’s ERB(s) should be provided with the following:

the current IB or package insert and updates during the course of the study

ICF

relevant curricula vitae
13.3. Regulatory Considerations
This study will be conducted in accordance with:
1) consensus ethics principles derived from international ethics guidelines, 
including the Declaration of Helsinki and Council for International Organizations
of Medical Sciences (CIOMS) International Ethical Guidelines
2) applicable ICH GCP Guidelines
3) applicable laws and regulations
The investigator or designee will promptly submit the protocol to applicable ERB(s).
Lilly certifies that this study is being conducted under an active United States (US)
investigational new drug (IND) application at clinical sites.  All investigators (at IND and non-
IND sites) are expected to comply with GCP and all applicable local clinical trial regulations.
All or some of the obligations of the Sponsor will be assigned to a third-party organization.
An identification code assigned by the investigator to each patient will be used in lieu of the 
patient’s name to protect the patient’s identity when reporting AEs and/or other trial-related data.
13.3.1. Investigator Information
Physicians with a specialty in family practice, internal medicine, or endocrinology, who are 
experienced in treating patients with diabetes mellitus with basal insulin, may participate as
investigators in this clinical trial provided they can demonstrate adequate experience in the 
conduct of clinical research studies.
13.3.2. Protocol Signatures
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study.  
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signed page to a Lilly representative.

I4L-GH-ABET(a) Clinical Protocol
Page 55
LY2963016
13.3.3. Final Report Signature
The investigator will sign the final CSR for this study, indicating agreement with the analyses, 
results, and conclusions of the report.
The CSR coordinating investigator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study. 
The investigator with the most enrolled patients will serve as the CSR coordinating investigator.  
If this investigator is unable to fulfill this function, another investigator will be chosen by Lilly to 
serve as the CSR coordinating investigator.
The sponsor’s responsible medical officer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study.

I4L-GH-ABET(a) Clinical Protocol
Page 56
LY2963016
14. References
[ADA] American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting 
hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on 
Hypoglycemia. Diabetes Care. 2005;28(5):1245-1249. 
Anderson RT, Skovlund SE, Marrero D, Levine DW, Meadows K, Brod M, Balkrishnan R. 
Development and validation of the insulin treatment satisfaction questionnaire. Clin Ther. 
2004;26(4):565-578.  
Bennett PH. Classification and diagnosis of diabetes mellitus and impaired glucose tolerance. In:  
Pickup J, Williams G, editors. Textbook of Diabetes, Vol 1. Oxford: Blackwell Scientific 
Publications; 1991:37-44.
Blevins TC, Dahl D, Rosenstock J, Ilag LL, Huster WJ, Zielonka JS, Pollom RK, Prince MJ.
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) 
in patients with type 1 diabetes in a randomized c ontrolled trial: the ELEMENT 1 study. 
Diabetes Obes Metab. 2015;17(8):726-733.
Chinese Diabetes Society. China T2DM prevention and treatment guideline (2013). Chin J
Diabetes Mellitus. 2014;6(7):447-498.
Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis; for the AT.LANTUS Study Group. 
Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: 
comparison of two treatment algorithms using insulin glargine. Diabetes Care.
2005;28(6):1282-1288.
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, 
Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin.
2010;60(4):207-221.
Lantus [US package insert]. Bridgewater, NJ: Sanofi-Aventis; 2010.
Mathieu C, Robbrecht S. Reaching glycaemic targets while minimizing hypoglycaemia in 
insulin-treated type 2 diabetes patients. Diabetes Obes Metab. 2008;10(Suppl 2):14-23.
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B,
American Diabetes Association, European Association for Study of Diabetes. Medical 
management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and 
adjustment of therapy: a consensus statement of the American Diabetes Association and the 
European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
Pieber TR, Eugène-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin 
in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. 
Diabetes Care. 2000;23(2):157-162.
Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The 
treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of 
type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-3086.
Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced 
hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with 
human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28(4):950-955.

I4L-GH-ABET(a) Clinical Protocol
Page 57
LY2963016
Rosenstock J, Hollander P, Bhargava A, Ilag LL, Pollom RK, Zielonka JS, Huster WJ, Prince 
MJ. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) 
in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin 
glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes 
Metab. 2015;17(8):734-741.
Yki-Järvinen H, Dressler A, Ziemen M, HOE 901/3002 Study Group. Less nocturnal 
hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared 
with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 
901/3002 Study Group. Diabetes Care. 2000;23(8):1130-1136.
Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K, 
Tulokas T, Hulme S, Hardy K, McNulty S, Hänninen J, Levänen H, Lahdenperä S, Lehtonen 
R, Ryysy L. Insulin glargine or NPH combined with metformin in type 2 diabetes: the 
LANMET study. Diabetologia. 2006;49(3):442-451.

I4L-GH-ABET(a) Clinical Protocol
Page 58
LY2963016
Attachment 1.Protocol ABET Study Schedule

LY2963016
I4L-GH-ABET(a) Clinical Protocol
Page 59
Study Schedule, Protocol I4L-GH-ABET
Visit
Description of Event
1
2
3*
4
5*
6
7*
8
9*
10
11*
12
13*
14
15*
16
17*
18
801
ED#
Week of Study
-2
0
1
2
3
4
5
6
7
8
10
12
14
16
18
20
22
24
28
Allowable Deviation
(days)a
±7
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±7
Telephone Visit
x
x
x
x
x
x
x
x
Clinic Visit
x
x
x
x
x
x
x
x
x
x
x
x
Screen Inclusion
Informed Consent
Obtained
x
Patient Number
Assigned
x
Randomization
x
Clinic Assessments
Medical History and Pre-
existing Conditions
x
Physical Exam
x
Height
x
Weight
x
x
x
x
x
x
x
x
x
x
x
Vital Signs (sitting)
SBP, DBP, and HR
x
x
x
x
x
x
x
x
x
x
x
Concom Medsc
x
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
x
x
Adverse Eventsc
x
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
x
x
Hypoglycemic Episodesc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
x
x
7-pt SMBGe,f
xe
xe
xe
xe
xe
xf
4-pt SMBGc
xc
xc
xc
xc
xc
xc
xc
xc
x
Previous insulin exposure
x
Study Drug/Device
Dispense Glucose Meter and 
Suppliesg
x
xg
xg
xg
xg
xg
xg
xg
xg
xg

LY2963016
I4L-GH-ABET(a) Clinical Protocol
Page 60
Visit
Description of Event
1
2
3*
4
5*
6
7*
8
9*
10
11*
12
13*
14
15*
16
17*
18
801
ED#
Week of Study
-2
0
1
2
3
4
5
6
7
8
10
12
14
16
18
20
22
24
28
Allowable Deviation
(days)a
±7
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±7
Telephone Visit
x
x
x
x
x
x
x
x
Clinic Visit
x
x
x
x
x
x
x
x
x
x
x
x
Glucometer Trainingb
xb
Dispense Pre-filled Pens
x
x
x
x
x
x
Training on signs/symptoms 
of hypo/hyperglycemiab
xb
Injection Technique
Trainingb
xb
BG Level Monitoring 
Trainingb
xb
xb
Distribute Study Diary
x
x
x
x
x
x
x
x
x
x
x
Diary Use Trainingb
xb
xb
Diet and Exercise 
Counselingb
xb
Training on Signs/Symptoms 
of Insulin Reactions
x
Adjust Insulin Dose (if 
Applicable)
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
Collect Study Drug
x
x
x
x
x
x
x
Collect Study Diaryh
xh
xh
xh
xh
xh
xh
xh
xh
xh
xh
Transfer Diary Data to 
eCRF (InForm™)
Insulin Therapy Dose
(day prior to visit)
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
7-pt SMBG Profilee,f
xe
xe
xe
xe
xe
xf

LY2963016
I4L-GH-ABET(a) Clinical Protocol
Page 61
Visit
Description of Event
1
2
3*
4
5*
6
7*
8
9*
10
11*
12
13*
14
15*
16
17*
18
801
ED#
Week of Study
-2
0
1
2
3
4
5
6
7
8
10
12
14
16
18
20
22
24
28
Allowable Deviation
(days)a
±7
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±7
Telephone Visit
x
x
x
x
x
x
x
x
Clinic Visit
x
x
x
x
x
x
x
x
x
x
x
x
4-pt SMBGi
xi
xi
xi
xi
xi
xi
xi
xi
xi
Lab Assessmentsj
Chemistry
x
x
x
Hematology
x
x
x
Pregnancy Screenk
xk
ECG (local)
x
HbA1c
x
x
x
x
x
x
x
x
x
Anti-Glargine Antibody Titerl
xl
xl
xl
xl
xl
xl
Collection of Serum Samples 
for Biomarkers (Fasting)d
xd
xd
xd
xd
Fasting Serum Glucosed
xd
xd
xd
Other - Transfer Data
to eCRF (InForm)
Administer ITSQm,n
xm
xm
xm
Xm,n

LY2963016
I4L-GH-ABET(a) Clinical Protocol
Page 62
Abbreviations:  BG = blood glucose; Concom Meds = concomitant medications; DBP = diastolic blood pressure; eCRF = electronic case report form; ED = early 
discontinuation; ECG = electrocardiogram; HbA1c = hemoglobin A1c; HR = heart rate; ITSQ = Insulin Treatment Satisfaction Questionnaire; pt = point; SBP 
= systolic blood pressure; SMBG = self-monitored blood glucose.
* Telephone visit.
#
Patients who discontinue early from the study will complete Visit 801.
a
For visit window purposes, the visit will end on the last day the patient completes a study procedure or assessment.  Visits should occur within the visit 
intervals indicated.  The timing of visits (including allowable deviations) should be based on time postrandomisation.
b
Additional training should be provided as needed throughout the study.
c
Adverse events, hypoglycemic episodes, concomitant medications and the last 3 available profiles of 4-point SMBG reported at telephone visits should be 
recorded on the eCRF at the next office visit.  The 4 points are: before morning, mid-day, and evening meals, and at bedtime.
d
The measurements should be done fasting before breakfast.
e
Patients should perform two 7-point SMBG profiles during the 2-week period prior to these visits (preferably most recent readings).  The 7-points are before
the morning, midday, and evening meals; 2 hours after the morning, midday meal, and evening meal; at bedtime.
f
Transfer values from the study diary if available.
g
Dispense glucose meter supplies as needed; may not be at every visit. 
h
Study sites will retain study diaries. 
i
The 3 days of 4-point SMBG values used as a reference from the telephone visit need to be validated and entered into the eCRF from the source diaries.  
These values should be within 1 week (or 2 weeks, if applicable) prior to the telephone visit preceding the office visit when data are transferred to eCRF.  In 
certain instances (for example, between Visits 2 and 4), it may be from the same days as those used for the 7-point SMBGs.
j
Analyses should be performed at a central laboratory unless otherwise noted and can be repeated for cause in case of adverse events.
k
Serum pregnancy test will be performed on all females of childbearing potential at Visit 1 and when clinically indicated, and will be analyzed by a central
laboratory.  Urine pregnancy tests at other visits can be accepted per local regulations.  A urine pregnancy test may be repeated locally for any visits if 
considered necessary by the investigators and/or in compliance with local regulations.
l
Blood samples for immunogenicity testing will be collected to determine antibody production against LY2963016 or Lantus®.
m Study sites will retain questionnaires.  
n
This questionnaire should be administered only if the patient has received at least 1 dose of study drug.
  

I4L-GH-ABET(a) Clinical Protocol
Page 63
LY2963016
Attachment 2.Protocol ABET Clinical Laboratory Tests
Clinical Laboratory Tests
Hematologya
Clinical Chemistrya
Serum Concentrations of:
Sodium
Potassium
Total bilirubin
Direct bilirubin
Indirect bilirubin
Alkaline phosphatase
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Blood urea nitrogen (BUN)
Creatinine
Albumin
Fasting serum glucose 
Hemoglobin
Hematocrit
Erythrocyte count (RBC)
Leukocytes (WBC)
Platelets
Neutrophils, Segmented
Lymphocytes
Monocytes
Eosinophils
Basophils
Other
Pregnancy testb
Hemoglobin A1ca
Anti-Glargine Antibodiesa
Serum for Biomarkers Nonpharmacogenetic 
Biomarkers (C-peptide)
Abbreviations: RBC = red blood cell; WBC = white blood cell
a
All laboratory tests to be performed at a central laboratory, unless specified otherwise.
b
Serum pregnancy tests will be performed on all females of childbearing potential at Visit 1 (and when clinically 
indicated) and will be analyzed by the central laboratory.  Urine pregnancy tests at other visits can be accepted 
per local regulations.  A urine pregnancy test may be repeated locally for any visits if considered necessary by 
the investigators and/or in compliance with local regulations.

I4L-GH-ABET(a) Clinical Protocol
Page 64
LY2963016
Attachment 3.Protocol ABET Estimated Sampling Summary
This table summarizes the purpose for sampling, sample types, estimated volume per sample, 
number of samples, and estimated total volume during the study.
Protocol I4L-GH-ABET Sampling Summary
Purpose
Sample 
Type
Estimated Amount 
per Sample 
Number Samples
Estimated Total 
Amount
Screening testsa
Blood
3 mL
2
6 mL
Standard laboratory testsa
Blood
3 mL
9
27 mL
Immunogenicity samples
Blood
8 mL
5
40 mL
Nonpharmacogenetic 
biomarkers (C-peptide)
Blood
6 mL
3
18 mL
Total
91 mL
Hepatic Monitoringb
Blood
-
-
3 - 30 mL
a
Additional samples may be drawn if needed for safety purposes.
b
Based on laboratory safety values, unscheduled hepatic monitoring testing may be performed as part of patient 
follow-up, in consultation with Lilly Designated Medical Monitor.

I4L-GH-ABET(a) Clinical Protocol
Page 65
LY2963016
Attachment 4. Protocol ABET Hepatic Monitoring Tests for 
Treatment Emergent Abnormality
Hepatic Monitoring Tests
Hepatic Hematologya
Haptoglobina
Hemoglobin
Hematocrit
Hepatic Coagulationa
RBC
Prothrombin Time
WBC
Prothrombin Time, INR
Neutrophils, segmented
Lymphocytes
Hepatic Serologiesa,b
Monocytes
Hepatitis A antibody, total
Eosinophils
Hepatitis A antibody, IgM
Basophils
Hepatitis B surface antigen
Platelets
Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistrya
Hepatitis C antibody
Total bilirubin
Hepatitis E antibody, IgG
Direct bilirubin
Hepatitis E antibody, IgM
Alkaline phosphatase
ALT
Anti-nuclear antibodya
AST
GGT
CPK 
Anti-smooth muscle antibodya
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma-glutamyl transpeptidase; IgG = Immunoglobulin G; IgM = Immunoglobulin M; INR = 
international normalized ratio; RBC = red blood cells; WBC = white blood cells.
a
Assayed by Lilly-designated central laboratory
b
Reflex/confirmation dependent on regulatory requirement and /or testing availability.

I4L-GH-ABET(a) Clinical Protocol
Page 66
LY2963016
Attachment 5.Protocol ABET World Health Organisation
(WHO)
Classification of Diabetes
Type 1 Diabetes Mellitus:  Type 1 diabetes mellitus is judged to be present when the classical 
symptoms of diabetes (thirst, polyuria, wasting and stupor, or coma) are associated with readily 
detectable concentrations of glucose and ketone bodies in the blood and urine.  Insulin treatment 
is necessary, not only to control hyperglycaemia, but to prevent spontaneous ketosis and death.
Type 2 Diabetes Mellitus:  Type 2 diabetes mellitus, although often asymptomatic, may also 
present with classical hyperglycaemic symptoms (thirst, polyuria, weight loss), but despite 
hyperglycaemia, ketone bodies are present in only low concentrations in the blood and urine.  
Coma is rare in type 2 diabetes, but may result from extreme hyperglycaemia and 
hyperosmolarity; lactic acidosis or ketoacidosis can also occur in fulminating illness (for 
example, severe infection or mesenteric artery thrombosis) due to an acute increase in insulin 
requirements, but spontaneous ketosis does not occur.  Some patients with type 2 diabetes later 
progress to a state of absolute insulin deficiency (Bennett 1991).

I4L-GH-ABET(a) Clinical Protocol
Page 67
LY2963016
Attachment 6.Protocol Amendment I4L-GH-ABET(a)
Summary:  A Prospective, Randomized, Open-Label 
Comparison of a Long-Acting Basal Insulin Analog 
LY2963016 to Lantus® in Adult Chinese Patients with Type 
2 Diabetes Mellitus
Overview
Protocol I4L-GH-ABET has been amended.  The new protocol is indicated by amendment (a) 
and will be used to conduct the study in place of any preceding version of the protocol.
The overall changes and rationale for the changes made to this protocol are as follows:

Estimated first patient visit and last patient visit in synopsis were updated.

Visit 801 was changed from telephone visit to clinic visit to mitigate the risk of source 
data inaccuracy.

For patients who discontinue from the study, completion of Visit 801 was added to avoid 
missing of Visit 801.

Tests of fasting serum glucose at Visit 2, Visit 18 or ED were added in study schedule 
(Attachment 1) as a complementation of self-monitored blood glucose (SMBG) pre-
morning value and c-peptide in data interpretation. And in Attachment 2, fasting serum 
glucose was added.

For serious adverse events after study completion or patient discontinuation in 
Section 10.3.1.1, related paragraph was updated according to current protocol template 
(version 11.0).

Infuse database is no longer in use, so it was replaced by Clintrial.

For treatment-emergent adverse event, the definition was revised from events newly 
reported or worsened after randomizationto those after first study treatment to exclude 
events occurred or worsened after randomization and prior to first dose.  Definition of 
TEAE in Section 4 was also updated per current clinical protocol template (version 11.0).

In Attachment 3, estimated sampling for standard laboratory test was updated, and total 
amount was changed accordingly.

For hepatic safety monitoring in Section 10.3.3, elevated ALT or AST > 3X ULN or 
elevated total bilirubin > 2X ULN was changed to elevated ALT or AST ≥3X ULN or 
elevated total bilirubin ≥2X ULN.

I4L-GH-ABET(a) Clinical Protocol
Page 68
LY2963016
Revised Protocol Sections
Note:
Deletions have been identified by strikethroughs.
Additions have been identified by the use of underscore.
2.
Synopsis
Length of Study:  
Estimated first patient visit:  Mar 20178               Estimated last patient visit:  Feb 201920
4.
Abbreviations and Definitions
treatment emergent 
adverse event (TEAE)
Any untoward medical occurrence that either occurs or worsens at any time after 
treatment baseline and that does not necessarily have a causal relationship with this 
treatment. Treatment-emergent adverse event:  An untoward medical occurrence that 
emerges during a defined treatment period, having been absent pretreatment, or worsens 
relative to the pretreatment state, and does not necessarily have to have a causal 
relationship with this treatment.
7.1.
Summary of Study Design
At approximately 4-week post-treatment endpoint (Visit 801), patients will have a final 
telephoneclinic visit at which information will be collected according to the Study Schedule 
(Attachment 1).  The starting dose is 10 units (U), which will be titrated by the weekly dosing
algorithm as described in Section 9.5 until fasting blood glucose (FBG) reaches ≤100 mg/dL 
(5.6 mmol/L) (weekly-base titration till Visit 10 and titration as needed afterwards.  The insulin 
doses can be adjusted between intervals at discretion of the investigators.  The titration procedure 
during the study will occur as described in Section 9.5.
End of study (trial) is the date of the last visit or last scheduled procedure shown in the Study 
Schedule for the last active patient in the study.
Figure ABET.7.1 illustrates the study design.

I4L-GH-ABET(a) Clinical Protocol
Page 69
LY2963016
7.2.2.4.
Follow-up Visit (Visit 801)
Patients will receive a telephone callcome to the investigator site approximately 4 weeks after the 
last treatment visit, at which time information will be discussed and recorded according to the 

I4L-GH-ABET(a) Clinical Protocol
Page 70
LY2963016
Study Schedule (Attachment 1).  Note:  The previous day’s insulin dose will be recorded if the 
patient has continued to take insulin.
Patients who discontinue early from the study will undergo all the end of study procedures and 
complete Visit 801 as outlined in Attachment 1. 
10.3.1.1.
Serious Adverse Events
The investigator does not need to actively monitor patients for adverse events once the trial has 
ended, unless provided otherwise in the protocol.  However, if an investigator becomes aware of 
SAEs occurring to a patient after the patient’s participation in the trial has ended, the investigator 
should report the SAEs to the sponsor, regardless of the investigator’s opinion of causation, and 
the SAEs will be entered in the pharmacovigilance system at the sponsor. Investigators are not 
obligated to actively seek AEs or SAEs in subjects once they have discontinued and/or 
completed the study (the patient summary CRF has been completed).  However, if the 
investigator learns of any SAE, including a death, at any time after a subject has been discharged 
from the study, and he/she considers the event reasonably possibly related to the study treatment 
or study participation, the investigator must promptly notify Lilly.
10.3.3.
Safety Monitoring
If a study patient experiences elevated ALT or AST >≥3X ULN or elevated total bilirubin >≥
2X ULN, clinical and laboratory monitoring should be initiated by the investigator. Details for 
hepatic monitoring depend upon the severity and persistence of observed laboratory test 
abnormalities.  To ensure patient safety and comply with regulatory guidance, the investigator is 
to consult with the Lilly designated medical monitor regarding collection of specific 
recommended clinical information and follow-up laboratory tests.  See Attachment 2 and 
Attachment 4.
10.4.2.1.
Nonpharmacogenetic Biomarker Evaluations
This study will employ sample collection.  Samples will be collected for nonpharmacogenetic 
biomarker investigation where local regulations allow.  BloodFasting serum samples will be 
collected at the times specified in the Study Schedule (Attachment 1).
Fasting sSamples being collected will be used to measure C-peptide to support trial
interpretation.
12.2.4.
Concomitant Therapy
Concomitant medications, including previous therapies for diabetes, will be summarized by 
different categories and treatment group using the FAS population. All concomitant therapies 
that originally mapped using the WHODRUG dictionary in the InFuseClintrial database will be 
further classified using anatomical, therapeutic chemical code for reporting purpose. Analyses 
will use test Fisher's Exact Test or Pearson’s Chi-square test.

I4L-GH-ABET(a) Clinical Protocol
Page 71
LY2963016
12.2.9.3.
Adverse Events
Adverse events will be listed by patient, system organ class, Medical Dictionary for Regulatory 
Activities® (MedDRA) preferred term, severity, and relationship to the study disease, drug, 
device, or procedure for all patients.  Adverse events will be summarized as treatment-emergent 
adverse events (TEAEs) for the FAS.  Treatment-emergent adverse events are defined as events 
that are newly reported after first study treatment following randomization, or reported to worsen 
in severity from randomizationbaseline. The proportion of patients experiencing each TEAE 
will be presented by preferred term, system organ class, and treatment group. The proportion of 
patients experiencing each TEAE that are assessed as possibly related to the study disease, drug, 
device, or procedures will also be summarized. The number and proportion of patients will be 
presented and compared by treatment using Fisher’s exact test or Pearson’s chi-square test for 
the FAS. 

LY2963016
I4L-GH-ABET(a) Clinical Protocol
Page 72
Attachment 1.
Protocol ABET Study Schedule
Visit
Description of Event
1
2
3*
4
5*
6
7*
8
9*
10
11*
12
13*
14
15*
16
17*
18
801*
ED#
Week of Study
-2
0
1
2
3
4
5
6
7
8
10
12
14
16
18
20
22
24
28
Allowable Deviation
(days)a
±7
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±3
±2
±7
Telephone Visit
x
x
x
x
x
x
x
x
x
Clinic Visit
x
x
x
x
x
x
x
x
x
x
x
x
Clinic Assessments
Concom Medsc,d
x
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xd
x
Adverse Eventsc,d
x
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xd
x
Hypoglycemic Episodesc,d
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xc
x
xd
x
4-pt SMBGc,d
xc
xc
xc
xc
xc
xc
xc
xc
xd
Study Drug/Device
Distribute Study Diary
x
x
x
x
x
x
x
x
x
x
x
Transfer Diary Data to 
eCRF (InForm™)
Insulin Therapy Dose
(day prior to visit)
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
xd
x
4-pt SMBGd,i
xi
xi
xi
xi
xi
xi
xi
xi
xd,i
xi
Lab Assessmentsj
Collection of Serum Samples 
for Biomarkers (Fasting)d
xd
xd
xd
xd
Fasting Serum Glucosed
xd
xd
xd

LY2963016
I4L-GH-ABET(a) Clinical Protocol
Page 73
#
Patients who discontinue early from the study will complete Visit 801.
c
Adverse events, hypoglycemic episodes, concomitant medications and the last 3 available profiles of 4-point SMBG reported at telephone visits should be 
recorded on the eCRF at the next office visit, or at Visit 801.  The 4 points are: before morning, mid-day, and evening meals, and at bedtime.
d
Information will be collected during a telephone visit and will be recorded on the eCRF.  Site documentation will serve as the source for this telephone visit, 
as the patient will not be returning the paper diary to the site. The measurements should be done fasting before breakfast.

I4L-GH-ABET(a) Clinical Protocol
Page 74
LY2963016
Attachment 2.
Protocol ABET Clinical Laboratory Tests
Hematologya
Clinical Chemistrya
Serum Concentrations of:
Sodium
Potassium
Total bilirubin
Direct bilirubin
Indirect bilirubin
Alkaline phosphatase
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Blood urea nitrogen (BUN)
Creatinine
Albumin
Fasting serum glucose
Hemoglobin
Hematocrit
Erythrocyte count (RBC)
Leukocytes (WBC)
Platelets
Neutrophils, Segmented
Lymphocytes
Monocytes
Eosinophils
Basophils
Other
Pregnancy testb
Hemoglobin A1ca
Anti-Glargine Antibodiesa
Serum for Biomarkers Nonpharmacogenetic
Biomarkers (C-peptide)
Attachment 3.
Protocol ABET Estimated Sampling Summary
Purpose
Sample 
Type
Estimated Amount 
per Sample 
Number Samples
Estimated Total 
Amount
Screening testsa
Blood
3 mL
2
6 mL
Standard laboratory testsa
Blood
3 mL
89
2427 mL
Immunogenicity samples
Blood
8 mL
5
40 mL
Nonpharmacogenetic 
biomarkers (C-peptide)
Blood
6 mL
3
18 mL
Total
8891 mL
Hepatic Monitoringb
Blood
-
-
3 - 30 mL